US6995192B2 - Radiation-curable prepolymers - Google Patents
Radiation-curable prepolymers Download PDFInfo
- Publication number
- US6995192B2 US6995192B2 US10/640,294 US64029403A US6995192B2 US 6995192 B2 US6995192 B2 US 6995192B2 US 64029403 A US64029403 A US 64029403A US 6995192 B2 US6995192 B2 US 6995192B2
- Authority
- US
- United States
- Prior art keywords
- alkyl
- substituted
- alkylene
- hydroxy
- ethylenically unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
- 229920002635 polyurethane Polymers 0.000 claims abstract description 151
- 239000000203 mixture Substances 0.000 claims abstract description 73
- 150000001875 compounds Chemical class 0.000 claims abstract description 41
- 150000001412 amines Chemical class 0.000 claims abstract description 31
- 239000004814 polyurethane Substances 0.000 claims abstract description 25
- 239000006085 branching agent Substances 0.000 claims abstract description 17
- 239000005056 polyisocyanate Substances 0.000 claims abstract description 13
- 229920001228 polyisocyanate Polymers 0.000 claims abstract description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 12
- 238000007334 copolymerization reaction Methods 0.000 claims abstract description 9
- -1 poly(ethylene glycol) Polymers 0.000 claims description 350
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 80
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 64
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 33
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 26
- 125000005250 alkyl acrylate group Chemical group 0.000 claims description 25
- 150000002431 hydrogen Chemical group 0.000 claims description 20
- 125000001931 aliphatic group Chemical group 0.000 claims description 19
- 125000005442 diisocyanate group Chemical group 0.000 claims description 19
- 229920001223 polyethylene glycol Polymers 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 16
- ARXKVVRQIIOZGF-UHFFFAOYSA-N 1,2,4-butanetriol Chemical compound OCCC(O)CO ARXKVVRQIIOZGF-UHFFFAOYSA-N 0.000 claims description 16
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 16
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 16
- 150000002440 hydroxy compounds Chemical class 0.000 claims description 15
- 229920005862 polyol Polymers 0.000 claims description 15
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 14
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 13
- 150000002367 halogens Chemical class 0.000 claims description 13
- 229920001451 polypropylene glycol Polymers 0.000 claims description 12
- 150000003077 polyols Chemical class 0.000 claims description 10
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 claims description 9
- 229920001400 block copolymer Polymers 0.000 claims description 9
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 claims description 9
- 238000006116 polymerization reaction Methods 0.000 claims description 9
- ATOUXIOKEJWULN-UHFFFAOYSA-N 1,6-diisocyanato-2,2,4-trimethylhexane Chemical compound O=C=NCCC(C)CC(C)(C)CN=C=O ATOUXIOKEJWULN-UHFFFAOYSA-N 0.000 claims description 8
- KGRVJHAUYBGFFP-UHFFFAOYSA-N 2,2'-Methylenebis(4-methyl-6-tert-butylphenol) Chemical compound CC(C)(C)C1=CC(C)=CC(CC=2C(=C(C=C(C)C=2)C(C)(C)C)O)=C1O KGRVJHAUYBGFFP-UHFFFAOYSA-N 0.000 claims description 8
- UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 8
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 8
- 239000004386 Erythritol Substances 0.000 claims description 8
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- KQWGXHWJMSMDJJ-UHFFFAOYSA-N cyclohexyl isocyanate Chemical compound O=C=NC1CCCCC1 KQWGXHWJMSMDJJ-UHFFFAOYSA-N 0.000 claims description 8
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 8
- 235000019414 erythritol Nutrition 0.000 claims description 8
- 229940009714 erythritol Drugs 0.000 claims description 8
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000600 sorbitol Substances 0.000 claims description 8
- ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 claims description 7
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 claims description 7
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 claims description 7
- 125000004406 C3-C8 cycloalkylene group Chemical group 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- QXJQHYBHAIHNGG-UHFFFAOYSA-N trimethylolethane Chemical compound OCC(C)(CO)CO QXJQHYBHAIHNGG-UHFFFAOYSA-N 0.000 claims description 7
- 150000002009 diols Chemical class 0.000 claims description 6
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229920005906 polyester polyol Polymers 0.000 claims description 5
- 125000006686 (C1-C24) alkyl group Chemical group 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000041 C6-C10 aryl group Chemical class 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 150000002016 disaccharides Chemical class 0.000 claims description 4
- 150000002772 monosaccharides Chemical class 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- DVKJHBMWWAPEIU-UHFFFAOYSA-N toluene 2,4-diisocyanate Chemical compound CC1=CC=C(N=C=O)C=C1N=C=O DVKJHBMWWAPEIU-UHFFFAOYSA-N 0.000 claims 14
- 229940044192 2-hydroxyethyl methacrylate Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 abstract description 82
- 238000004519 manufacturing process Methods 0.000 abstract description 20
- 229920001515 polyalkylene glycol Polymers 0.000 abstract description 9
- 230000000704 physical effect Effects 0.000 abstract description 3
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 57
- 239000005058 Isophorone diisocyanate Substances 0.000 description 56
- 229920001983 poloxamer Polymers 0.000 description 55
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 53
- 238000002360 preparation method Methods 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 239000000243 solution Substances 0.000 description 34
- 230000005855 radiation Effects 0.000 description 31
- 125000002348 vinylic group Chemical group 0.000 description 30
- 239000003054 catalyst Substances 0.000 description 27
- 229910052757 nitrogen Inorganic materials 0.000 description 27
- 238000004132 cross linking Methods 0.000 description 26
- 150000003254 radicals Chemical class 0.000 description 26
- GJKGAPPUXSSCFI-UHFFFAOYSA-N 2-Hydroxy-4'-(2-hydroxyethoxy)-2-methylpropiophenone Chemical compound CC(C)(O)C(=O)C1=CC=C(OCCO)C=C1 GJKGAPPUXSSCFI-UHFFFAOYSA-N 0.000 description 21
- 239000000155 melt Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 20
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 19
- UKLDJPRMSDWDSL-UHFFFAOYSA-L [dibutyl(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(CCCC)OC(=O)CCCCCCCCCCC UKLDJPRMSDWDSL-UHFFFAOYSA-L 0.000 description 19
- 229920000642 polymer Polymers 0.000 description 19
- 239000012975 dibutyltin dilaurate Substances 0.000 description 18
- 230000035484 reaction time Effects 0.000 description 17
- 102100026735 Coagulation factor VIII Human genes 0.000 description 16
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 16
- 230000008569 process Effects 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 239000003618 borate buffered saline Substances 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 0 *C(=O)OCC(=O)N[6*].*C1=C([7*])C(=O)N([H])C1=O.C.C.[H]N1C(=O)CC(=C)C1=O Chemical compound *C(=O)OCC(=O)N[6*].*C1=C([7*])C(=O)N([H])C1=O.C.C.[H]N1C(=O)CC(=C)C1=O 0.000 description 10
- 239000003999 initiator Substances 0.000 description 10
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 10
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000470 constituent Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000036571 hydration Effects 0.000 description 7
- 238000006703 hydration reaction Methods 0.000 description 7
- 238000000108 ultra-filtration Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 229920002534 Polyethylene Glycol 1450 Polymers 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000012266 salt solution Substances 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 5
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 description 4
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 229920001730 Moisture cure polyurethane Polymers 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 4
- 125000000732 arylene group Chemical group 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 150000003335 secondary amines Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229940095095 2-hydroxyethyl acrylate Drugs 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 229920002596 Polyethylene Glycol 900 Polymers 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- IGWHDMPTQKSDTL-JXOAFFINSA-N TMP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IGWHDMPTQKSDTL-JXOAFFINSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- 239000000460 chlorine Chemical group 0.000 description 3
- 229910052801 chlorine Chemical group 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 2
- XIXNSLABECPEMI-VURMDHGXSA-N (z)-2-[2-[(2-methylpropan-2-yl)oxycarbonylamino]-1,3-thiazol-4-yl]pent-2-enoic acid Chemical compound CC\C=C(/C(O)=O)C1=CSC(NC(=O)OC(C)(C)C)=N1 XIXNSLABECPEMI-VURMDHGXSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical compound CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 2
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-Tetramethylpiperidine Substances CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 2
- YEJRWHAVMIAJKC-UHFFFAOYSA-N 4-Butyrolactone Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 2
- OZJPLYNZGCXSJM-UHFFFAOYSA-N 5-valerolactone Chemical compound O=C1CCCCO1 OZJPLYNZGCXSJM-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 2
- KAKZBPTYRLMSJV-UHFFFAOYSA-N Butadiene Chemical compound C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- GYCMBHHDWRMZGG-UHFFFAOYSA-N Methylacrylonitrile Chemical compound CC(=C)C#N GYCMBHHDWRMZGG-UHFFFAOYSA-N 0.000 description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 2
- YUDRVAHLXDBKSR-UHFFFAOYSA-N [CH]1CCCCC1 Chemical compound [CH]1CCCCC1 YUDRVAHLXDBKSR-UHFFFAOYSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000005120 alkyl cycloalkyl alkyl group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 210000003323 beak Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- QQVIHTHCMHWDBS-UHFFFAOYSA-N isophthalic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 2
- 229940102838 methylmethacrylate Drugs 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- 238000010019 resist printing Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- FMQPBWHSNCRVQJ-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-yl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(C(F)(F)F)C(F)(F)F FMQPBWHSNCRVQJ-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- LCPUCXXYIYXLJY-UHFFFAOYSA-N 1,1,2,4,4,4-hexafluorobutyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OC(F)(F)C(F)CC(F)(F)F LCPUCXXYIYXLJY-UHFFFAOYSA-N 0.000 description 1
- 125000005838 1,3-cyclopentylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:2])C([H])([H])C1([H])[*:1] 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004955 1,4-cyclohexylene group Chemical group [H]C1([H])C([H])([H])C([H])([*:1])C([H])([H])C([H])([H])C1([H])[*:2] 0.000 description 1
- CTXUTPWZJZHRJC-UHFFFAOYSA-N 1-ethenylpyrrole Chemical compound C=CN1C=CC=C1 CTXUTPWZJZHRJC-UHFFFAOYSA-N 0.000 description 1
- VOCDJQSAMZARGX-UHFFFAOYSA-N 1-ethenylpyrrolidine-2,5-dione Chemical compound C=CN1C(=O)CCC1=O VOCDJQSAMZARGX-UHFFFAOYSA-N 0.000 description 1
- 239000012956 1-hydroxycyclohexylphenyl-ketone Substances 0.000 description 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QTKPMCIBUROOGY-UHFFFAOYSA-N 2,2,2-trifluoroethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(F)(F)F QTKPMCIBUROOGY-UHFFFAOYSA-N 0.000 description 1
- VFFFESPCCPXZOQ-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol;oxirane Chemical compound C1CO1.OCC(CO)(CO)CO VFFFESPCCPXZOQ-UHFFFAOYSA-N 0.000 description 1
- GOHPTLYPQCTZSE-UHFFFAOYSA-N 2,2-dimethylsuccinic acid Chemical compound OC(=O)C(C)(C)CC(O)=O GOHPTLYPQCTZSE-UHFFFAOYSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JAHNSTQSQJOJLO-UHFFFAOYSA-N 2-(3-fluorophenyl)-1h-imidazole Chemical compound FC1=CC=CC(C=2NC=CN=2)=C1 JAHNSTQSQJOJLO-UHFFFAOYSA-N 0.000 description 1
- OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
- BEWCNXNIQCLWHP-UHFFFAOYSA-N 2-(tert-butylamino)ethyl 2-methylprop-2-enoate Chemical group CC(=C)C(=O)OCCNC(C)(C)C BEWCNXNIQCLWHP-UHFFFAOYSA-N 0.000 description 1
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 description 1
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- BQZJOQXSCSZQPS-UHFFFAOYSA-N 2-methoxy-1,2-diphenylethanone Chemical compound C=1C=CC=CC=1C(OC)C(=O)C1=CC=CC=C1 BQZJOQXSCSZQPS-UHFFFAOYSA-N 0.000 description 1
- YVHAOWGRHCPODY-UHFFFAOYSA-N 3,3-dimethylbutane-1,2-diol Chemical compound CC(C)(C)C(O)CO YVHAOWGRHCPODY-UHFFFAOYSA-N 0.000 description 1
- ZIFLDVXQTMSDJE-UHFFFAOYSA-N 3-[[dimethyl-[3-(2-methylprop-2-enoyloxy)propyl]silyl]oxy-dimethylsilyl]propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](C)(C)O[Si](C)(C)CCCOC(=O)C(C)=C ZIFLDVXQTMSDJE-UHFFFAOYSA-N 0.000 description 1
- NWBTXZPDTSKZJU-UHFFFAOYSA-N 3-[dimethyl(trimethylsilyloxy)silyl]propyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](C)(C)O[Si](C)(C)C NWBTXZPDTSKZJU-UHFFFAOYSA-N 0.000 description 1
- WJIOHMVWGVGWJW-UHFFFAOYSA-N 3-methyl-n-[4-[(3-methylpyrazole-1-carbonyl)amino]butyl]pyrazole-1-carboxamide Chemical compound N1=C(C)C=CN1C(=O)NCCCCNC(=O)N1N=C(C)C=C1 WJIOHMVWGVGWJW-UHFFFAOYSA-N 0.000 description 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 description 1
- KFDVPJUYSDEJTH-UHFFFAOYSA-N 4-ethenylpyridine Chemical compound C=CC1=CC=NC=C1 KFDVPJUYSDEJTH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FKAWETHEYBZGSR-UHFFFAOYSA-N C=C(CC(N1)=O)C1=O Chemical compound C=C(CC(N1)=O)C1=O FKAWETHEYBZGSR-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 1
- NFFRLZCGHFMGEP-UHFFFAOYSA-N OC(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)=C(C(C(N(F)F)(F)F)(F)F)C(C(C(F)(F)F)(F)F)=S)=O Chemical compound OC(C(C(C(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F)=C(C(C(N(F)F)(F)F)(F)F)C(C(C(F)(F)F)(F)F)=S)=O NFFRLZCGHFMGEP-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000463 Poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) Polymers 0.000 description 1
- 229920000464 Poly(propylene glycol)-block-poly(ethylene glycol)-block-poly(propylene glycol) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- IAXXETNIOYFMLW-COPLHBTASA-N [(1s,3s,4s)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-methylprop-2-enoate Chemical compound C1C[C@]2(C)[C@@H](OC(=O)C(=C)C)C[C@H]1C2(C)C IAXXETNIOYFMLW-COPLHBTASA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- MQDJYUACMFCOFT-UHFFFAOYSA-N bis[2-(1-hydroxycyclohexyl)phenyl]methanone Chemical compound C=1C=CC=C(C(=O)C=2C(=CC=CC=2)C2(O)CCCCC2)C=1C1(O)CCCCC1 MQDJYUACMFCOFT-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229930188620 butyrolactone Natural products 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical compound OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 description 1
- YACLQRRMGMJLJV-UHFFFAOYSA-N chloroprene Chemical compound ClC(=C)C=C YACLQRRMGMJLJV-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- IFDVQVHZEKPUSC-UHFFFAOYSA-N cyclohex-3-ene-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCC=CC1C(O)=O IFDVQVHZEKPUSC-UHFFFAOYSA-N 0.000 description 1
- QSAWQNUELGIYBC-UHFFFAOYSA-N cyclohexane-1,2-dicarboxylic acid Chemical compound OC(=O)C1CCCCC1C(O)=O QSAWQNUELGIYBC-UHFFFAOYSA-N 0.000 description 1
- KBLWLMPSVYBVDK-UHFFFAOYSA-N cyclohexyl prop-2-enoate Chemical compound C=CC(=O)OC1CCCCC1 KBLWLMPSVYBVDK-UHFFFAOYSA-N 0.000 description 1
- 125000004956 cyclohexylene group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- MEGHWIAOTJPCHQ-UHFFFAOYSA-N ethenyl butanoate Chemical compound CCCC(=O)OC=C MEGHWIAOTJPCHQ-UHFFFAOYSA-N 0.000 description 1
- BLZSRIYYOIZLJL-UHFFFAOYSA-N ethenyl pentanoate Chemical compound CCCCC(=O)OC=C BLZSRIYYOIZLJL-UHFFFAOYSA-N 0.000 description 1
- UIWXSTHGICQLQT-UHFFFAOYSA-N ethenyl propanoate Chemical compound CCC(=O)OC=C UIWXSTHGICQLQT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940119545 isobornyl methacrylate Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- HNEGQIOMVPPMNR-NSCUHMNNSA-N mesaconic acid Chemical compound OC(=O)C(/C)=C/C(O)=O HNEGQIOMVPPMNR-NSCUHMNNSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- LVHBHZANLOWSRM-UHFFFAOYSA-N methylenebutanedioic acid Natural products OC(=O)CC(=C)C(O)=O LVHBHZANLOWSRM-UHFFFAOYSA-N 0.000 description 1
- HNEGQIOMVPPMNR-UHFFFAOYSA-N methylfumaric acid Natural products OC(=O)C(C)=CC(O)=O HNEGQIOMVPPMNR-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- OMNKZBIFPJNNIO-UHFFFAOYSA-N n-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=O)CC(C)(C)NC(=O)C=C OMNKZBIFPJNNIO-UHFFFAOYSA-N 0.000 description 1
- PZUGJLOCXUNFLM-UHFFFAOYSA-N n-ethenylaniline Chemical compound C=CNC1=CC=CC=C1 PZUGJLOCXUNFLM-UHFFFAOYSA-N 0.000 description 1
- KKFHAJHLJHVUDM-UHFFFAOYSA-N n-vinylcarbazole Chemical compound C1=CC=C2N(C=C)C3=CC=CC=C3C2=C1 KKFHAJHLJHVUDM-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- WSGCRAOTEDLMFQ-UHFFFAOYSA-N nonan-5-one Chemical compound CCCCC(=O)CCCC WSGCRAOTEDLMFQ-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920002120 photoresistant polymer Polymers 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000909 polytetrahydrofuran Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- HJWLCRVIBGQPNF-UHFFFAOYSA-N prop-2-enylbenzene Chemical compound C=CCC1=CC=CC=C1 HJWLCRVIBGQPNF-UHFFFAOYSA-N 0.000 description 1
- LYBIZMNPXTXVMV-UHFFFAOYSA-N propan-2-yl prop-2-enoate Chemical compound CC(C)OC(=O)C=C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 1
- NHARPDSAXCBDDR-UHFFFAOYSA-N propyl 2-methylprop-2-enoate Chemical compound CCCOC(=O)C(C)=C NHARPDSAXCBDDR-UHFFFAOYSA-N 0.000 description 1
- PNXMTCDJUBJHQJ-UHFFFAOYSA-N propyl prop-2-enoate Chemical compound CCCOC(=O)C=C PNXMTCDJUBJHQJ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052594 sapphire Inorganic materials 0.000 description 1
- 239000010980 sapphire Substances 0.000 description 1
- MNCGMVDMOKPCSQ-UHFFFAOYSA-M sodium;2-phenylethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=CC1=CC=CC=C1 MNCGMVDMOKPCSQ-UHFFFAOYSA-M 0.000 description 1
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- UFDHBDMSHIXOKF-UHFFFAOYSA-N tetrahydrophthalic acid Natural products OC(=O)C1=C(C(O)=O)CCCC1 UFDHBDMSHIXOKF-UHFFFAOYSA-N 0.000 description 1
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 1
- 125000005425 toluyl group Chemical group 0.000 description 1
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 1
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/67—Unsaturated compounds having active hydrogen
- C08G18/671—Unsaturated compounds having only one group containing active hydrogen
- C08G18/672—Esters of acrylic or alkyl acrylic acid having only one group containing active hydrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/67—Unsaturated compounds having active hydrogen
- C08G18/675—Low-molecular-weight compounds
- C08G18/677—Low-molecular-weight compounds containing heteroatoms other than oxygen and the nitrogen of primary or secondary amino groups
- C08G18/678—Low-molecular-weight compounds containing heteroatoms other than oxygen and the nitrogen of primary or secondary amino groups containing nitrogen
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
Definitions
- the present invention is related to radiation-curable prepolymers useful for making polymeric articles, preferably ophthalmic device, more preferably soft contact lenses.
- the present invention is related to water-soluble radiation-curable prepolymers.
- the present invention is related to methods for preparing radiation-curable prepolymers of the invention as well as methods for making a polymeric article, preferably ophthalmic devices, more preferably soft contact lenses from radiation-curable prepolymers of the invention.
- contact lenses can be used for cosmetics and the correction of visual acuity.
- the ideal contact lens is one which is not only comfortable to wear for extended periods of time, but also easily and reproducibly manufactured at minimum cost in time and labor.
- Contact lenses can be manufactured economically in large numbers by the so-called mold or full-mold process.
- Known contact lens-molding processes are described in, for example, PCT patent application no. WO/87/04390 or in EP-A 0 367 513.
- a predetermined amount of a polymerizable or crosslinkable material is placed in the female mold half and the mold is closed by placing the male mold half proximately to the female mold half to create a cavity having a desired geometry for a contact lens.
- a surplus of polymerizable or crosslinkable material is used so that when the male and female halves of the mold are closed, the excess amount of the material is expelled out into an overflow area adjacent to the mold cavity.
- the polymerizable or crosslinkable material remaining within the mold is polymerized or cross-linked with the delivery of radiation thereto through UV light, heat action, or another non-thermal methods. Since the geometry of the ophthalmic lens is specifically defined by the cavity between the male and female mold halves and since the geometry of the edge of the ophthalmic lens is defined by the contour of the two mold halves in the area where they make contact, a contact lens is manufactured into a final form between typically male and female mold halves, with no additional finishing work on the surface of the lens or the edges of the lens. Such full-mold process can reduce cost in the production of contact lenses. However, In a typical molding process, a contact lens, which is removed from the mold after curing, needs to undergo the other manufacturing processes such as hydration/extraction and sterilization. Therefore, there is still room for further reducing manufacturing cost of contact lenses.
- U.S. Pat. Nos. 5,508,317, 5,583,463, 5,789,464, and 5,849,810 describe an improved manufacturing process for economically producing contact lenses in large numbers.
- a water-soluble composition of a prepolymer which is a water-soluble photo-crosslinkable polyvinyl alcohol By using a water-soluble composition of a prepolymer which is a water-soluble photo-crosslinkable polyvinyl alcohol, a finished lens of optical quality can be produced in a mold within a few seconds without the necessity for subsequent extraction or finishing steps to the contact lens.
- contact lenses can be manufactured at considerably low cost and thus it is possible to produce disposable contact lenses that are discarded by the user after a single use.
- contact lenses made from a water-soluble photo-crosslinkable polyvinyl alcohol prepolymer do not always posses all of most desirable physical properties, for example, such as elasticity and durability, for the intended uses.
- a radiation-curable prepolymer prepared by reacting an isocyanate-capped polyurethane with an ethylenically unsaturated amine or an ethylenically unsaturated monohydroxy compound or a mixture thereof, wherein the isocyanate-capped polyurethane is a copolymerization production of: (a) at least one polyalkylene glycol; (b) at least one branching agent having at least three hydroxy groups; and (c) at least one di- or polyisocyanate.
- the present invention provides a solventless method for preparing a radiation-curable prepolymer of the invention.
- the solventless method comprises: (I) preparing a melted reaction mixture comprising (a) one or more polyalkylene glycols, (b) one or more branching agents each having at least three hydroxy group, and (c) at least one di- or polyisocyanate, wherein the stoichiometry of components (a), (b) and (c) in the melted reaction mixture is chosen so that the number of NCO equivalents of component (c) is greater than the sum of OH equivalents of components (a) and (b); (II) reacting components (a) and (b) with component (c) in the melted reaction mixture at a desired temperature to form an isocyanate-capping polyurethane; and (III) reacting the formed isocyanate-capping polyurethane, without intermediate isolation, with an ethylenically unsaturated amine (primary or secondary amine) or an e
- the present invention provides a polymer which is a product of radiation-crosslinking of an above-described radiation-curable prepolymer of the invention in the presence or preferably in the absence of one or more additional vinylic comonomers.
- the present invention provides a medical device, preferably an ophthalmic device, more preferably a contact lens, which is obtained by crosslinking an above-described radiation-curable prepolymer of the invention in the presence or preferably in the absence of one or more additional vinylic comonomers.
- the present invention provides a method for producing an ophthalmic device, the method comprising the steps of: a) introducing an above-described radiation-curable prepolymer of the invention, which is liquid or readily meltable at room temperature, and which is essentially free from solvents, into a mold, in the presence or preferably in the absence of one or more additional vinylic comonomers, and optionally in the presence of a photo-initiator, b) crosslinking by actinic radiation the radiation-curable prepolymer, and c) opening the mold so that the article can be removed from the mold.
- the present invention provides a method for producing an ophthalmic device, the method comprising the steps of: a) introducing an aqueous solution of an above-described radiation-curable prepolymer of the invention, in the presence or preferably in the absence of one or more additional vinylic comonomers, and optionally in the presence of a photo-initiator, into a mold; b) crosslinking by actinic radiation the radiation-curable prepolymer, and c) opening the mold so that the article can be removed from the mold.
- the present invention relates to a radiation-curable prepolymer, which is obtained by introducing ethylenically unsaturated groups into an isocyanate-capped polyurethane.
- a “radiation-curable prepolymer” refers to a starting polymer which can be crosslinked upon actinic radiation to obtain a crosslinked polymer having a molecular weight much higher than the starting polymer.
- actinic radiation examples include UV irradiation, ionized radiation (e.g. gamma ray or X-ray irradiation), microwave irradiation, and the like.
- An isocyanate-capped polyurethane of the invention is a copolymerization product of
- n, m and p independently of one another, preferably each denote a number from 0 to 50, whereby the sum of (n+m+p) is 8 to 50. Most preferably, n, m and p, independently of one another, each denote a number from 0 to 25, whereby the sum of (n+m+p) is 9 to 25.
- q preferably signifies a number from 1 to 20.
- n and m independently of one another, are each a number from 0 to 100, preferably 0 to 50, and most preferably 0 to 25, and the sum of (n+m) is 5 to 100, preferably 8 to 50, most preferably 9 to 25.
- n is a number from 5 to 100, preferably 8 to 50, most preferably 9 to 25.
- Exemplary poly(alkylene glycol)s include, but are not limited to a poly(ethylene glycol), a poly(propylene glycol), a poly(ethylene glycol)/poly(propylene glycol) block polymer, a poly(ethylene glycol)/poly(propylene glycol)/poly(butylene glycol) block polymer, a polytetrahydrofuran, a poloxamer, and a mixture thereof.
- Poloxamers are hydroxy terminated tri-block copolymers with the structure PEG-PPG-PEG (where “PEG” is poly(ethylene glycol) and “PPG” is poly(propylene glycol)) and are available, for example, under the tradename PLURONIC®.
- PEG poly(ethylene glycol)
- PPG poly(propylene glycol)
- the order of PEG and PPG blocks can be reversed creating block copolymers with the structure PPG-PEG-PPG, which are available, for example, under the tradename PLURONIC-R®.
- a considerable number of poloxamers is known, differing merely in the molecular weight and in the PEG/PPG ratio.
- Poloxamer 101 has a PEG/PPG weight ratio of about 10/90 and poloxamer 108 having a PEG/PPG weight ratio of about 80/20.
- Polyoxypropylene-polyoxyethylene block copolymers can also be designed with hydrophilic blocks comprising a random mix of ethylene oxide and propylene oxide repeating units. To maintain the hydrophilic character of the block, ethylene oxide will predominate. Similarly, the hydrophobic block can be a mixture of ethylene oxide and propylene oxide repeating units. Such block copolymers are available under the tradename PLURADOT®.
- the weight average molecular weight of poloxamers may vary within wide limits.
- a branching agent of formula (2) is preferably a linear or branched C 3 to C 12 aliphatic polyol, more preferably a linear or branched C 3 to C 8 aliphatic polyol.
- the variable x in formula (2) is preferably a number from 3 to 12, more preferably a number from 3 to 8, even more preferably a number from 3 to 6, and most preferably the number 3.
- Examples of a branching agent of formula (2) are glycerol, diglycerol, triglycerol, 1,1,1-trishydroxymethylethane, 1,1,1-trishydroxymethylpropane, 1,2,4-butanetriol, 1,2,6-hexanetriol, erythritol, pentaerythritol, di- or tripentaerythritol, arabitol, sorbitol, disorbitol or mannitol and mixtures thereof.
- Preferred compounds of formula (2) are glycerol, 1,1,1-tris-hydroxymethylpropane, 1,2,4-butanetriol, erythritol, pentaerythritol, arabitol or sorbitol.
- a group of preferred branching agents of formula (2) comprises glycerol, 1,1,1-trishydroxymethylpropane, pentaerythritol, and pentaerythritol ethoxylate.
- a branching agent is reaction products of the above-mentioned polyhydroxy compounds of formula (2) with a dicarboxylic acid or with a derivative of a dicarboxylic acid, e.g. a dicarboxylic acid anhydride, ester or halide, as well as a diol, whereby oligomeric polyester polyols are obtained, or reaction products of the above-mentioned polyhydroxy compounds with a glycol, whereby oligomeric polyether polyols are obtained.
- a branching agent is also suitable as a branching agent according to (b) are reaction products of the above-mentioned polyhydroxy compounds of formula (2) with a dicarboxylic acid or with a derivative of a dicarboxylic acid, e.g. a dicarboxylic acid anhydride, ester or halide, as well as a diol, whereby oligomeric polyester polyols are obtained, or reaction products of the above-mentioned polyhydroxy compounds with a
- the branching agent is preferably an oligomeric reaction product of a compound of formula (2), wherein the above-mentioned meanings and preferences apply, with an aliphatic or cycloaliphatic dicarboxylic acid having 3 to 12 carbon atoms, or an aromatic dicarboxylic acid having 5 to 15 carbon atoms, or an appropriate derivative thereof, e.g. a corresponding dicarboxylic acid anhydride, ester or halide, as well as a diol as chain extender.
- a compound of formula (2) wherein the above-mentioned meanings and preferences apply, with an aliphatic or cycloaliphatic dicarboxylic acid having 3 to 12 carbon atoms, or an aromatic dicarboxylic acid having 5 to 15 carbon atoms, or an appropriate derivative thereof, e.g. a corresponding dicarboxylic acid anhydride, ester or halide, as well as a diol as chain extender.
- dicarboxylic acids examples include malonic acid, succinic acid, 2,2-dimethylsuccinic acid, glutaric acid, adipic acid, pimelic acid, sebacic acid, tetrahydrophthalic acid, hexahydrophthalic acid, phthalic acid, isophthalic acid, terephthalic acid, maleic acid or fumaric acid, as well as the corresponding dicarboxylic acid esters, halides or anhydrides.
- Appropriate diols are e.g. linear or branched C 2 –C 20 -alkyl-diols.
- branching agent is a cycloaliphatic polyol
- the branching agent may be e.g. cyclopentane or preferably a cyclohexane, which is respectively substituted by 3 to 5 and preferably by 3 or 4 hydroxy groups and bears no further substituents or hetero atoms.
- Further suitable cycloaliphatic polyols according to (b) are represented by unsubstituted mono- or disaccharides, e.g. glucose, fructose, mannose, galactose, maltose, lactose or saccharose.
- y is preferably a number from 2 to 4, more preferably 2.
- R 5 is the radical of a linear or branched C 3 –C 18 -alkylene, an unsubstituted or C 1 –C 4 -alkyl-substituted or C 1 –C 4 -alkoxy-substituted C 6 –C 10 -arylene, a C 7 –C 18 -aralkylene, a C 6 –C 10 -arylene-C 1 –C 2 -alkylene-C 6 –C 10 -arylene, a C 3 –C 8 -cycloalkylene, a C 3 –C 8 -cycloalkylene-C 1 –C 6 -alkylene, a C 3 –C 8 -cycloalkylene-C 1 –C 2 -alkylene-C 3 –C 8 -cycloalkylene, or a C 1 –C 6 -alkylene-C 3 –C 8 -cycloalkylene-C 3 –C 8 -cycl
- R 5 is the radical of an alkylene
- R 5 is preferably a linear or branched C 4 –C 12 -alkylene radical, more preferably a linear or branched C 6 –C 10 -alkylene radical.
- preferred alkylene radicals are 1,4-butylene, 2,2-dimethyl-1,4-butylene, 1,5-pentylene, 2,2-dimethyl-1,5-pentylene, 1,6-hexylene, 2,2,3- or 2,2,4-trimethyl-1,5-pentylene, 2,2-dimethyl-1,6-hexylene, 2,2,3- or 2,2,4- or 2,2,5-trimethyl-1,6-hexylene, 2,2-dimethyl-1,7-heptylene, 2,2,3- or 2,2,4- or 2,2,5- or 2,2,6-trimethyl-1,7-heptylene, 1,8-octylene, 2,2-dimethyl-1,8-octylene or 2,2,3- or 2,2,4-
- R 5 is the radical of an arylene
- the arylene is preferably naphthylene, more preferably phenylene. If the arylene is substituted, a substituent is preferably located in ortho position to an isocyanate group.
- substituted arylene are 1-methyl-2,4-phenylene, 1,5-dimethyl-2,4-diphenylene, 1-methoxy-2,4-phenylene or 1-methyl-2,7-naphthylene.
- R 5 is the radical of an aralkylene
- the aralkylene is preferably naphthylalkylene, more preferably phenylalkylene.
- the alkylene group in aralkylene preferably contains 1 to 12, more preferably 1 to 6, even more preferably 1 to 4, most preferably 1 to 2 C-atoms.
- a few examples are 1,3- or 1,4-benzylene, naphth-2-yl-7-methylene, 6-methyl-1,3- or -1,4-benzylene, 6-methoxy-1,3- or -1,4-benzylene.
- R 5 is the radical of a cycloalkylene
- the cycloalkylene is preferably C 5 –C 6 -cycloalkylene, more preferably cyclohexylene which is respectively unsubstituted or methyl-substituted.
- 1,3-cyclobutylene 1,3-cyclopentylene, 1,3- or 1,4-cyclohexylene, 1,3- or 1,4-cycloheptylene, 1,3- or 1,4- or 1,5-cyclooctylene, 4-methyl-1,3-cyclopentylene, 4-methyl-1,3-cyclohexylene, 4,4-dimethyl-1,3-cyclohexylene, 3-methyl- or 3,3-dimethyl-1,4-cyclohexylene, 3,5-dimethyl-1,3-cyclohexylene, 2,4-dimethyl-1,4-cyclohexylene.
- R 5 is the radical of a cycloalkylene-alkylene
- the cycloalkylene-alkylene is preferably cyclopentylene-C 1 –C 4 -alkylene, more preferably cyclohexylene-C 1 –C 4 -alkylene which is respectively unsubstituted or substituted once or several times by C 1 –C 4 -alkyl, especially methyl.
- the group cycloalkylene-alkylene preferably denotes cyclohexylene-ethylene and most preferably denotes cyclohexylene-methylene, which is respectively unsubstituted in the cyclohexylene radical or substituted by 1 to 3 methyl groups.
- cyclopent-1-yl-3-methylene 3-methyl-cyclopent-1-yl-3-methylene, 3,4-dimethyl-cyclopent-1-yl-3-methylene, 3,4,4-trimethyl-cyclopent-1-yl-3-methylene, cyclohex-1-yl-3- or -4-methylene, 3- or 4- or 5-methyl-cyclohex-1-yl-3- or -4-methylene, 3,4- or 3,5-dimethyl-cyclohex-1-yl-3- or -4-methylene, 3,4,5- or 3,4,4- or 3,5,5-trimethyl-cyclohex-1-yl-3-or -4-methylene.
- R 5 is the radical of an alkylene-cycloalkylene-alkylene
- the alkylene-cycloalkylene-alkylene is preferably C 1 –C 4 -alkylene-cyclopentylene-C 1 –C 4 -alkylene and especially C 1 –C 4 -alkylene-cyclohexylene-C 1 –C 4 -alkylene, which is respectively unsubstituted or substituted once or several times by C 1 –C 4 -alkyl, most preferably methyl.
- the group alkylene-cycloalkylene-alkylene preferably denotes ethylene-cyclohexylene-ethylene and most preferably methylene-cyclohexylene-methylene, which is respectively unsubstituted in the cyclohexylene radical or substituted by 1 to 3 methyl groups.
- cyclopentane-1,3-dimethylene 3-methyl-cyclopentane-1,3-dimethylene 3,4-dimethyl-cyclopentane-1,3-dimethylene, 3,4,4-trimethyl-cyclopentane-1,3-dimethylene, cyclohexane-1,3- or -1,4-dimethylene, 3- or 4- or 5-methyl-cyclohexane-1,3- or -1,4-dimethylene, 3,4- or 3,5-dimethyl-cyclohexane-1,3- or -1,4-dimethylene, 3,4,5- or 3,4,4- or 3,5,5-trimethyl-cyclohexane-1,3- or -1,4-dimethylene.
- R 5 is the radial of a cycloalkylene-alkylene-cycloalkylene
- the cycloalkylene-alkylene-cycloalkylene is preferably C 5 –C 6 -cycloalkylene-methylene-C 5 –C 6 -cycloalkylene, which may respectively be unsubstituted in the cycloalkyl ring by one or more methyl groups.
- R 5 is the radial of an arylene-alkylene-arylene
- the arylene-alkylene-arylene is preferably phenylene-methylene-phenylene, which may respectively be unsubstituted in the phenyl ring by one or more methyl groups.
- Examples of especially preferred diisocyanates of formula (3) are isophorone diisocyanate (IPDI), methylenebis(cyclohexyl-isocyanate), 1,6-diisocyanato-2,2,4-trimethyl-n-hexane (TMDI), methylenebis(phenyl-isocyanate) or hexamethylene-diisocyanate (HMDI).
- IPDI isophorone diisocyanate
- TMDI 1,6-diisocyanato-2,2,4-trimethyl-n-hexane
- HMDI hexamethylene-diisocyanate
- a prepolymer of the present invention is prepared by reacting an isocyanate-capped polyurethane of the present invention with an ethylenically unsaturated amine (primary or secondary amine) or an ethylenically unsaturated monohydroxy compound.
- Examples of ethylenically unsaturated monohydroxy compound includes, without limitation, hydroxy-substituted lower alkylacrylates and -methacrylates, hydroxy-substituted lower alkyl-acrylamides and -methacrylamides, hydroxy-substituted lower alkylvinyl-ethers.
- Examples of hydroxy-substituted lower alkylacrylates and -methacrylates are 2-hydroxyethyl acrylate and 2-hydroxyethyl methacrylate.
- An ethylenically unsaturated amine has formula (4), (4′) or (4′′) In which, I, j and k, independent of one another, are o or 1;
- Aryl R 6 is a carbocyclic aromatic radical, which is unsubstituted or substituted by preferably lower alkyl (C 1 –C 4 ) or lower alkoxy (C 1 –C 4 ). Examples are phenyl, toluyl, xylyl, methoxyphenyl, t-butoxyphenyl, naphthyl or phenanthryl.
- Cycloalkyl R 6 is preferably C 5 –C 6 cycloalkyl and most preferably cyclohexyl that is unsubstituted or substituted by methyl.
- Some examples are cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, 4-methyl-cyclopentyl, 4-methyl-cyclohexyl, 4,4-dimethyl-cyclohexyl, 3-methyl- or 3,3-dimethyl-cyclohexyl, 3,5-dimethyl-cyclohexyl and 2,4-dimethyl-cyclohexyl.
- R 6 is cycloalkylalkyl, it is preferably cyclopentyl-C 1 –C 4 alkyl and especially cyclohexyl-C 1 –C 4 alkyl, each unsubstituted or mono- or poly-substituted by C 1 –C 4 alkyl, especially methyl. More preferably, the group cycloalkyl-alkyl is cyclohexylethyl and, most preferably, cyclohexylmethyl, each unsubstituted or substituted in the cyclohexyl radical by from 1 to 3 methyl groups.
- R 6 is alkylcycloalkylalkyl, it is preferably C 1 –C 4 alkyl-cyclopentyl-C 1 –C 4 alkyl and especially C 1 –C 4 alkyl-cyclohexyl-C 1 –C 4 alkyl, each unsubstituted or mono- or poly-substituted by C 1 –C 4 alkyl, especially methyl. More preferably, the group alkylcycloalkylalkyl is ethylcyclohexylethyl and, most preferably, is methylcyclohexylmethyl, each unsubstituted or substituted in the cyclohexyl radical by from 1 to 3 methyl groups.
- R 6 is cycloalkylalkylcycloalkyl or arylalkylaryl, it is preferably C 5 –C 6 cycloalkyl-methyl-C 5 –C 6 cycloalkyl or phenylmethylphenyl, each of which may be unsubstituted or substituted in the cycloalkyl or phenyl ring by one or more methyl groups.
- Suitable substituents on the ethylenically unsaturated C 2 –C 24 radical Q are, for example, C 1 –C 4 alkoxy, halogen, phenyl or carboxy.
- Q is, for example, a radical of formula wherein q is the number 0 or 1,
- Z′ is a phenylene radical
- it is, for example, unsubstituted or methyl- or methoxy-substituted 1,2-, 1,3- or 1,4-phenylene.
- Z′ as a phenylene radical is 1,3-or 1,4-phenylene.
- Z′ is an aralkylene radical
- Z′ is, for example, unsubstituted or methyl- or methoxy-substituted benzylene, wherein the methylene group is bonded to the amine nitrogen in each case.
- Z′ as an aralkylene radical is the 1,3- or 1,4-phenylenemethylene radical, wherein the methylene group is bonded to the amine nitrogen —NH— in each case.
- Z′ is preferably unsubstituted or methyl- or methoxy-substituted phenylene or phenylenemethylene or C 1 –C 12 alkylene, more preferably 1,3- or 1,4-phenylene or C 1 –C 6 alkylene, especially C 1 –C 2 alkylene and most preferably methylene.
- q is the number 1 or, preferably, the number 0.
- R 10 is preferably hydrogen, methyl or chlorine and most preferably hydrogen or methyl.
- R 8 and R 9 independently of the other, is preferably hydrogen, carboxy, chlorine, methyl or phenyl.
- R 8 is hydrogen, chlorine, methyl or phenyl and R 9 is hydrogen or carboxy. Most preferably, R 8 and R 9 are each hydrogen.
- radicals Q correspond to formula (5) wherein p is 0, R 10 is hydrogen or methyl, R 8 is hydrogen, methyl, chlorine or phenyl and R 9 is hydrogen or carboxy.
- radicals Q correspond to the above formula (5) wherein p is 1, Z′ is 1,3- or 1,4-phenylene or C 1 –C 6 alkylene, especially C 1 –C 2 alkylene, R 10 is hydrogen or methyl and R 8 and R 9 are each hydrogen.
- radicals Q are vinyl, 2-propenyl, allyl, 2-butenyl, o-, m- or p-vinylphenyl, vinylphenyl, vinylnaphthyl, allylphenyl, styryl, 2-carboxyvinyl, 2-chloro-2-carboxyvinyl, 1,2-dichloro-2-carboxyvinyl, 1,2-dimethyl-2-carboxyvinyl and 2-methyl-2-carboxyvinyl.
- Suitable ethylenically unsaturated amine are 2-(ter-butylamino)ethylmethacrylate (TBAM), and vinyl aniline.
- the isocayanate-capped polyurethane polymers according to the invention may be produced by following a solventless process.
- one or more polyalkylene glycols of formula (1) (component (a)) is mixed with one or more branching agents (component (b)) and the mixture is heated to and maintained at a melting temperature or above.
- at least one di- or polyisocyanate of formula (3) (component (c)) is added to the melted mixture to make a melted reaction mixture comprising component (a), component (b) and component (c) in a desired stoichiometry.
- the temperature of the melted reaction mixture is continuously and thoroughly stirred at the melting temperature or above and preferably under an inert atmosperic environment (for example, in nitrogen or argon atmosphere). Reaction is monitored by, for example, monitoring the isocyanate peak in FT-IR spectroscopy.
- Components (a)–(c) are all known compounds or compound mixtures, or may be obtained in accordance with methods known per se.
- components (a), (b), and (c) can be mixed together in a desired stoichiometry and the mixture then can be melted and maintained at a melting temperature or above to start reaction.
- the stoichiometry of components (a), (b) and (c) in the melted reaction mixture is advantageously chosen so that the number of NCO equivalents of component (c) is greater than the sum of OH equivalents of components (a) and (b).
- the stoichiometry of components (a), (b) and (c) in the melted reaction mixture is chosen so that the molar ratio of component (a) to component (b) to component (c) is about 4:1:7.
- the isocayanate-capped polyurethane polymers according to the invention may be produced by reacting components (a), (b), and (c) and optionally additional copolymerizable monomers in an inert solvent at a temperature of e.g. 30° C. to 150° C.
- Suitable inert solvents are aprotic, preferably polar solvents, for example hydrocarbon halides (chloroform, methylene chloride, trichloroethane, tetrachloroethane, chlorobenzene), ethers (tetrahydrofuran, dioxane), ketones (acetone, ethyl methyl ketone, dibutyl ketone, methyl isobutyl ketone), carboxylic acid esters and lactones (ethyl acetate, butyrolactone, valerolactone), alkylated carboxylic acid amides (N,N-dimethylacetamide, N-methylpyrrolidone), nitriles (acetonitrile), sulphones and sulphoxides (dimethyl sulphoxide, tetramethylene sulphone). Polar solvents are preferably employed.
- hydrocarbon halides chloroform, methylene chloride, t
- Suitable catalysts are for example metal salts such as alkali metal salts or tin salts of organic carboxylic acids, or tertiary amines, for example, (C 1 –C 6 -alkyl) 3 N (triethylamine, tri-n-butylamine), N-methylpyrrolidine, N-methylmorpholine, N,N-dimethylpiperidine, pyridine or 1,4-diaza-bicyclooctane.
- Tin salts have proved to be particularly effective, especially alkyl-tin salts of carboxylic acids, for example dibutyl tin dilaurate (DBTDL) and tin dioctoate.
- the catalyst is employed in the reaction e.g. in a molar ratio of 1:10 to 1:1000, preferably 1:50 to 1:750, most preferably ca. 1:100 to 1:500, respectively based on component (a).
- reaction times may vary within a broad range, whereby progress of the reaction can be followed well by monitoring the reduction of the isocyanate content in the reaction mixture.
- the isocyanate-capped polyurethane polymers of the invention is produced in a solventless process.
- a solventless process the production cost associated with solvent and its disposal can be eliminated.
- the obtained isocyanate-capping polyurentane can be reacted directly with an ethylenically unsaturated amine (primary or secondary amine) and an ethylenically unsaturated monohydroxy compound, to prepare a radiation-curable polyurethane prepolymer of the invention.
- the obtained isocyanate-capping polyurentane can be purified before reacting with a radiation-curable group-capping agent.
- Isolation and purification of the radiation-curable polyurethane prepolymer are effected by known processes, for example extraction, crystallization, re-crystallization, ultrafiltration or by chromatographic purification methods.
- the compounds are obtained in high yields and high purity.
- the present invention relates to a solventless process for the production of a radiation-curable polyurethane prepolymers.
- the method comprises the steps of: (I) preparing a melted reaction mixture comprising one or more polyalkylene glycols of formula (1) (component (a)), one or more branching agents (component (b)), and at least one di- or polyisocyanate of formula (3) (component (c)), wherein the stoichiometry of components (a), (b) and (c) in the melted reaction mixture is chosen so that the number of NCO equivalents of component (c) is greater than the sum of OH equivalents of components (a) and (b); (II) reacting components (a) and (b) with component (c) in the melted reaction mixture at a desired temperature to form an isocyanate-capping polyurethane; and (III) reacting the formed isocyanate-capping polyurethane, without intermediate isolation, with a radiation-curable group-capping agent, which
- the prepolymers according to the invention are radiation-curable, but uncrosslinked or at least substantially uncrosslinked; nevertheless, they are stable, i.e. spontaneous crosslinking due to homopolymerization does not take place substantially.
- radiation-curable in reference to a prepolymer means that the prepolymer can be crosslinked or polymerized by actinic radiation, including, for example, UV radiation, ionizing radiation such gamma radiation or X-rays, microwave, and the like.
- the radiation-curable prepolymers are advantageously liquid or readily meltable or water-soluble; the radiation-curable prepolymers are most preferably water-soluble.
- the average molecular weight of the radiation-curable prepolymers according to the invention may vary within a broad range. An average molecular weight of e.g. 1000 to 50,000 has proved to be advantageous for the radiation-curable prepolymers according to the invention.
- the radiation-curable prepolymers according to the invention may be purified in a manner known per se, for example by precipitation with acetone, dialysis or preferably by ultrafiltration.
- the radiation-curable prepolymers according to the invention may be obtained in extremely pure form, e.g. as solvent-free liquids or melts or as concentrated aqueous solutions, which are free from or at least substantially free from reaction products such as salts, and from starting materials or other non-polymeric constituents.
- the preferred purifying process for the prepolymers according to the invention may be carried out in a manner known per se.
- ultrafiltration may also be carried out continuously, until reaching the desired degree of purity.
- the desired degree of purity may be basically selected at any level, and is preferably set so that the content of undesired constituents in the prepolymers is e.g. ⁇ 0.001%, most preferably ⁇ 0.0001% (1 ppm).
- the prepolymers may additionally contain constituents which are acceptable from a physiological point of view, e.g. sodium chloride, whereby such constituents are advantageously present in an amount of ⁇ 1%, preferably ⁇ 0.1%, most preferably ⁇ 0.01%.
- the present invention relates to a polymer which is a product of crosslinking of a radiation-curable prepolymer of the invention (described-above) in the presence or preferably in the absence of one or more additional vinylic comonomers.
- the radiation-curable prepolymers according to the invention may be crosslinked in an extremely effective and well-directed manner upon actinic irradiation, in particular by UV irradiation. Crosslinking may take place in the presence or preferably in the absence of an additional vinylic comonomer. The resulting crosslinked polymers are insoluble in water.
- the present invention provides a medical device, preferably an ophthalmic device, more preferably a contact lens, which is obtained by crosslinking an above-described radiation-curable prepolymer of the invention in the presence of or preferably in the absence of one or more additional vinylic comonomers.
- a “medical device”, as used herein, refers to a device having surfaces that contact tissue, blood, or other bodily fluids of patients in the course of their operation or utility.
- Exemplary medical devices include: (1) extracorporeal devices for use in surgery such as blood oxygenators, blood pumps, blood sensors, tubing used to carry blood and the like which contact blood which is then returned to the patient; (2) prostheses implanted in a human or animal body such as vascular grafts, stents, pacemaker leads, heart valves, and the like that are implanted in blood vessels or in the heart; (3) devices for temporary intravascular use such as catheters, guide wires, and the like which are placed into blood vessels or the heart for purposes of monitoring or repair; and (4) ophthalmic devices.
- medical devices are ophthalmic devices.
- an “ophthalmic device”, as used herein, refers to a contact lens (hard or soft), an intraocular lens, a corneal onlay, and other ophthalmic devices (e.g., stents, or the like) used on or about the eye or ocular vicinity.
- a photo-initiator is suitably added which can initiate radical crosslinking.
- suitable photo-initiators which may be mentioned in particular are benzoin-methylether, 1-hydroxy-cyclo-hexyl-phenylketone, Darocure® 1173 or Irgacure® types.
- Crosslinking may be commenced by actinic radiation, e.g. UV light, or by ionized radiation, e.g. gamma rays or X-rays.
- Photo-crosslinking may also be carried out without adding a solvent, e.g. if the radiation-curable prepolymer is a liquid or readily meltable prepolymer, or it takes place in a suitable solvent.
- Suitable solvents are basically all solvents that dissolve the radiation-curable prepolymers according to the invention and optionally the additional vinylic comonomers, e.g. water, alcohols such as lower alkanols, e.g. ethanol or methanol, furthermore carboxylic acid amides, such as dimethyl-formamide, or dimethyl sulphoxide, and likewise mixtures of suitable solvents, e.g. mixtures of water with an alcohol, such as a water/ethanol or a water/methanol mixture.
- Photo-crosslinking is preferably effected whilst solvent-free or essentially solvent-free or directly from an aqueous solution of the prepolymers according to the invention, which may be obtained as the result of the preferred purification step, ultrafiltration, optionally after adding an additional vinylic comonomers.
- photo-crosslinking may be undertaken from a 15 to 90% aqueous solution.
- the process for the production of the crosslinked polymers according to the invention comprises radiation-crosslinking a radiation-curable prepolymer of the invention and optionally further copolymerizable monomers, especially in substantially pure form, i.e. for example after ultrafiltration once or several times whilst solvent-free or substantially solvent-free or in solution, especially in aqueous solution, in the presence or preferably in the absence of an additional vinylic comonomer, preferably using a photoinitiator.
- the vinylic comonomer which may be additionally used for photo-crosslinking in accordance with the invention may be hydrophilic, hydrophobic or may be a mixture of a hydrophobic and a hydrophilic vinylic monomer.
- Suitable vinylic monomers include especially those normally used for the manufacture of contact lenses.
- a “hydrophilic vinylic monomer” refers to a monomer which as a homopolymer typically yields a polymer that is water-soluble or can absorb at least 10 percent by weight water.
- a “hydrophobic vinylic monomer” refers to a monomer which as a homopolymer typically yields a polymer that is insoluble in water and can absorb less than 10 percent by weight water.
- a hydrophobic vinylic comonomer or a mixture of a hydrophobic vinylic comonomer with a hydrophilic vinylic comonomer, whereby this mixture contains at least 50 percent by weight of a hydrophobic vinyl comonomer.
- this mixture contains at least 50 percent by weight of a hydrophobic vinyl comonomer.
- Suitable hydrophobic vinylic comonomers include, without limitation, C 1 –C 18 -alkylacrylates and -methacrylates, C 3 –C 18 alkylacrylamides and -methacrylamides, acrylonitrile, methacrylonitrile, vinyl-C 1 –C 18 -alkanoates, C 2 –C 18 -alkenes, C 2 –C 18 -halo-alkenes, styrene, C 1 –C 6 -alkylstyrene, vinylalkylethers in which the alkyl moiety has 1 to 6 carbon atoms, C 2 –C 10 -perfluoralkyl-acrylates and -methacrylates or correspondingly partially fluorinated acrylates and methacrylates, C 3 –C 12 -perfluoralkyl-ethyl-thiocarbonylaminoethyl-acrylates and -methacrylates, acryloxy and methacryloxy-
- hydrophobic vinylic comonomers examples include methylacrylate, ethyl-acrylate, propylacrylate, isopropylacrylate, cyclohexylacrylate, 2-ethylhexylacrylate, methylmeth-acrylate, ethylmethacrylate, propylmethacrylate, vinyl acetate, vinyl propionate, vinyl butyrate, vinyl valerate, styrene, chloroprene, vinyl chloride, vinylidene chloride, acrylonitrile, 1-butene, butadiene, methacrylonitrile, vinyl toluene, vinyl ethyl ether, perfluorohexylethyl-thio-carbonyl-aminoethyl-methacrylate, isobornyl methacrylate, trifluoroethyl methacrylate, hexafluoro-isopropyl methacrylate, hexafluorobuty
- Suitable hydrophilic vinylic comonomers include, without limitation, hydroxy-substituted lower alkylacrylates and -methacrylates, acrylamide, methacrylamide, lower alkyl-acrylamides and -methacrylamides, ethoxylated acrylates and methacrylates, hydroxy-substituted lower alkyl-acrylamides and -methacrylamides, hydroxy-substituted lower alkylvinyl-ethers, sodium ethylene sulphonate, sodium styrene sulphonate, 2-acrylamido-2-methyl-propane-sulphonic acid, N-vinyl pyrrole, N-vinyl succinimide, N-vinyl pyrrolidone, 2- or 4-vinyl pyridine, acrylic acid, methacrylic acid, amino- (whereby the term “amino” also includes quaternary ammonium), mono-lower-alkylamino- or di-lower-
- hydrophilic vinylic comonomers examples include hydroxyethyl methacrylate, hydroxyethyl acrylate, acrylamide, methacrylamide, dimethylacrylamide, allyl alcohol, vinyl pyridine, vinyl pyrrolidone, glycerol methacrylate, N-(1,1-dimethyl-3-oxobutyl)acrylamide, and the like.
- Preferred hydrophobic vinylic comonomers are methyl methacrylate and vinyl acetate.
- Preferred hydrophilic vinylic comonomers are 2-hydroxyethyl methacrylate, N-vinyl pyrrolidone and acrylamide.
- the processing according to the invention for molding radiation-curable prepolymers into ophthalmic articles, especially contact lenses, may take place in a manner known per se, for example, photo-crosslinking of the radiation-curable prepolymers according to the invention in an appropriate contact lens mold.
- molded articles according to the invention apart from contact lenses, are e.g. intra-ocular lenses or eye dressings, furthermore biomedical articles which may be used in surgery, such as heart valves, artificial arteries or the like, also films or membranes, e.g. membranes for diffusion control, photo-structurable films for data storage, or photo resist materials, e.g. membranes or molded articles for etch resist printing or screen resist printing.
- the present invention provides a method for producing an ophthalmic device, the method comprising the steps of: a) introducing an above-described radiation-curable prepolymer of the invention, which is liquid or readily meltable at room temperature, and which is essentially free from solvents, into a mold, in the presence or preferably in the absence of one or more additional vinylic comonomers, and optionally in the presence of a photo-initiator, b) crosslinking by actinic radiation the radiation-curable prepolymer, and c) opening the mold so that the device can be removed from the mold.
- the present invention provides a method for producing an ophthalmic device, the method comprising the steps of: a) introducing an aqueous solution of an above-described radiation-curable prepolymer of the invention, in the presence or preferably in the absence of one or more additional vinylic comonomers, and optionally in the presence of a photo-initiator, into a mold; b) crosslinking by actinic radiation the radiation-curable prepolymer, and c) opening the mold so that the device can be removed from the mold.
- the radiation-curable prepolymers according to the invention may be introduced into a mold by methods known per se, especially conventional dispensing, e.g. dropwise addition. If vinylic comonomers are present, the comonomers employed are those mentioned above, in desired quantities. Any vinylic comonomers that are optionally present are advantageously first of all mixed with the prepolymer according to the invention and then introduced into the mold.
- Appropriate molds are made, for example, from polypropylene.
- Suitable materials for re-usable mounds are e.g. quartz, sapphire glass or metals.
- the molded articles to be produced are contact lenses, these may be produced in a manner known per se, e.g. in a conventional “spin-casting mold”, as described for example in U.S. Pat. No. 3,408,429, or by the so-called full mold process in a static form, as described e.g. in U.S. Pat. Nos. 4,347,198, 5,508,317, 5,583,463, 5,789,464, and 5,849,810.
- Crosslinking may be initiated in the mold e.g. by means of actinic radiation, such as UV irradiation, ionizing radiation (e.g., gamma or X-ray irradiation).
- actinic radiation such as UV irradiation, ionizing radiation (e.g., gamma or X-ray irradiation).
- photo-crosslinking is advantageously carried out in the presence of a photo-initiator which can initiate radical crosslinking.
- the photo-initiator is advantageously added to the prepolymers according to the invention prior to introducing them into the mold, preferably by mixing the polymers and the photo-initiator together.
- the amount of photo-initiator may be selected from a wide range, whereby an amount of up to 0.05 g/g polymer and especially up to 0.003 g/g polymer has proved favorable.
- crosslinking according to the invention may be effected in a very short time, e.g. in ⁇ 60 minutes, advantageously in ⁇ 20 minutes, preferably in ⁇ 10 minutes, most preferably in ⁇ 5 minutes, particularly preferably in 1 to 60 seconds and most particularly in 1 to 30 seconds.
- Opening of the mold so that the molded article can be removed from the mold may take place in a manner known per se.
- the molded article produced according to the invention is a contact lens which is produced solvent-free from an already purified prepolymer according to the invention, then after removal of the molded article, it is not normally necessary to follow up with purification steps such as extraction. This is because the prepolymers employed do not contain any undesired constituents of low molecular weight; consequently, the crosslinked product is also free or substantially free from such constituents and subsequent extraction can be dispensed with. Accordingly, the contact lens can be directly transformed in the usual way, by hydration, into a ready-to-use contact lens. Appropriate embodiments of hydration are known to the person skilled in the art, whereby ready-to-use contact lenses with very varied water content may be obtained.
- the contact lens is expanded, for example, in water, in an aqueous salt solution, especially an aqueous salt solution having an osmolarity of about 200 to 450 milli-osmole in 1000 ml (unit: mOsm/ml), preferably about 250 to 350 mOsm/l and especially about 300 mOsm/l, or in a mixture of water or an aqueous salt solution with a physiologically compatible polar organic solvent, e.g. glycerol.
- Preference is given to expansions of the article in water or in aqueous salt solutions.
- the aqueous salt solutions used for hydration are advantageously solutions of physiologically compatible salts, such as buffer salts conventionally used in the field of contact lens care, e.g. phosphate salts, or isotonizing agents conventionally used in the field of contact lens care, such as in particular alkali halides, e.g. sodium chloride, or solutions of mixtures thereof.
- physiologically compatible salts such as buffer salts conventionally used in the field of contact lens care, e.g. phosphate salts, or isotonizing agents conventionally used in the field of contact lens care, such as in particular alkali halides, e.g. sodium chloride, or solutions of mixtures thereof.
- physiologically compatible salts such as buffer salts conventionally used in the field of contact lens care, e.g. phosphate salts, or isotonizing agents conventionally used in the field of contact lens care, such as in particular alkali halides, e.g. sodium chloride, or solutions of mixtures thereof.
- the above-defined hydration fluids are preferably pure, i.e. free or substantially free from undesired constituents. This is most preferably pure water or an artificial lachrymal fluid as described above.
- the molded article produced according to the invention is a contact lens which is produced from an aqueous solution of an already purified prepolymer according to the invention, then the crosslinked product also does not contain any troublesome impurities. It is therefore not necessary to carry out subsequent extraction. Since crosslinking is carried out in an essentially aqueous solution, it is additionally unnecessary to carry out subsequent hydration.
- the contact lenses obtainable by this process are therefore notable, according to an advantageous embodiment, for the fact that they are suitable for their intended usage without extraction. By intended usage is understood, in this context, that the contact lenses can be used in the human eye.
- the contact lenses obtained according to the invention have a wide range of unusual and extremely advantageous properties.
- One of these properties which may be named is for example its excellent compatibility with the human cornea, which is based on a well-balanced relationship between water content, oxygen permeability and good mechanical properties including elasticity and durability.
- the contact lenses according to the invention have high resistance of shape. No changes in shape can be detected even after autoclaving at e.g. about 120° C.
- the contact lenses according to the invention can be produced from a radiation-curable prepolymer in a very simple and efficient way compared with the prior art. This is based on many factors. On the one hand, the starting materials may be acquired or produced inexpensively. Secondly, there is the advantage that the prepolymers are surprisingly stable, so that they may undergo a high degree of purification. Therefore, for crosslinking, a polymer may be used which requires practically no more subsequent purification, such as in particular complicated extraction of unpolymerized constituents. Furthermore, crosslinking may take place solvent-free or in aqueous solution, so that a subsequent solvent exchange or the hydration step is not necessary. Finally, photo-polymerization is effected within a short period, so that from this point of view also the production process for the contact lenses according to the invention may be set up in an extremely economic way.
- PEG, Poly(THF)-650, IPDI, and TMP are purchased from Aldrich Chemical. Pluronic and reverse Pluronic products are obtained from BASF. Irgacure 2959 is obtained from CIBA specialty corporation.
- FT-IR spectra are recorded on a BioRad FTS-175 spectrometer. Samples for IR analysis are prepared be smearing neat poly(urethane) samples between NaCl disks.
- Molecular sieves are activated by heating them at about 400° C. for several hours and then stored in a desiccator.
- viscosity is measured at 30 RPM, #16 spindle, at 25° C. using a Brookfield viscometer. The sample is centrifuged for 15 minutes at 4000 RPM prior to viscosity measurement.
- the percentage of NCO in samples is determined by titration Using Mettler Toledo Autotitrator.
- Pin Hole Test are carried out as follows: Lenses are punctured with a 22 gauge needle, folded in half and then rolled 2–3 times between fingers. If a lenses does not fracture, it is given a Pass rating.
- the water contents (%) of contact lenses are measured using an ATAGO CL-1 Refractometer or an ATAGO N2-E Refractometer.
- Tensile properties are measured using Lloyd Instrument Tester L-500 or equivalent and Lloyd Cell 5N, Class 0.5 or equvalent, with a strain rate of 200 mm/minute.
- poly(urethane) 1525-68 is mixed with 1.30 grams of TBAM at room temperature. The sample is checked by FT-IR and additional TBAM is added until the isocyante peak is no longer visible.
- a 30% solids water solution of photocurable poly(urethane) is prepared by adding 37.40 grams of an aqueous solution containing 0.043% Irgacure 2959. The sample is centrifuged for about 10 minutes at 4000 RPM and then chilled.
- Contact lenses are prepared from aqueous solutions containing about 30 weight percent polymer and 0.05 weight percent of Irgacure 2959.
- Poly(propylene) molds (FreshLook casting cups) are filled with poly(urethane) solution, and cured for 10 seconds at about 2.5 mW/cm 2 .
- Lenses are removed from the molds, placed in glass vials containing isotonic borate buffered saline (saline solution contained 0.005% poloxomer) and then sterilized.
- PEG-900 75.03 g
- Pluronic 17R2 9.355 g
- TMP (2.216 g) are combined and allowed to melt at 60° C.
- the melt is dried over 3A activated molecular seives for about 20 hours.
- IPDI 32.40 g
- DBTDL dibutlytindilaurate
- the temperature of the reaction mixture increased to about 90° C. soon after the addition of DBTDL.
- the reaction mixture is allowed to continue heating in a 60° C. oven for about 2 hours.
- the percent NCO in the sample is determined by titration to be close to the theoretically predicted value.
- Poly(urethane) 1525-66 is mixed at room temperature with 1.95 grams of TBAM.
- the sample is analyzed by FT-IR and additional TBAM is added dropwise until NCO is no longer present in FT-IR spectra.
- a 30% solids water solution of photocurable poly(urethane) is prepared by adding 39.41 grams of an aqueous solution containing 0.043% Irgacure 2959. The sample is centrifuged for about 10 minutes at 4000 RPM and then chilled.
- Poly(propylene) lens molds are filled with about 75 microliters of polymer solution and then closed. Poly(urethane) solutions are cured by subjecting the filled molds to about 2.2 mW/cm2 UV light (Light Stream lamp) for about 10 seconds. Molds are opened and lenses are placed in borate buffered saline. Lenses are then sterilized in an autoclave. Properties of lenses are given in table 3
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:0.75:6.63.
- the amount of catalyst DBTDL relative to the reaction component is about 0.01.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to the procedure described in Example 2.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:0.75:6.64.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0050.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:0.75:6.64.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0050.
- Radiation curable prepolymer is prepared by reacting HEA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:1.0:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0038.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:1.0:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0038.
- Radiation curable prepolymer is prepared by reacting HEA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pol(THF)-650, Pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.25:0.25:1.0:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0050.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, pol(THF)-650, Pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.25:0.25:1.0:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0050.
- Radiation curable prepolymer is prepared by reacting HEA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, Pluronic 17R2, ethylene glycol, TMP, and IPDI is a molar ratio of 3.8:0.25:0.5:0.5:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0109.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, Pluronic 17R2, ethylene glycol, TMP, and IPDI is a molar ratio of 3.8:0.2:0.28:0.75:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0046.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of PEG-1000, Pluronic 17R2, poly(THF)-650, TMP, and IPDI is a molar ratio of 3.25:0.25:0.50:1.0:7.0.
- the amount of catalyst DBTDL relative to the reaction component is about 0.0057.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 2.
- the stoichiometry of Pluronic 17R2, TMP, and IPDI is a molar ratio of 4.0:0.75:6.63.
- the amount of catalyst DBTDL relative to the reaction component is about 0.010.
- Radiation curable prepolymer is prepared by reacting HEMA with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 2 and in the presence of catalyst.
- the above NCO terminated poly(urethane) is converted to TBAM capped poly(urethane) in approximately 200 gram portions in 1-liter plastic beakers. To each sample of the NCO terminated poly(urethane) is added a calculated 1-equivalent of TBAM. Samples are mixed thoroughly using plastic rods and then checked by FT-IR. Additional TBAM is added dropwise until NCO is consumed. Aqueous solutions containing about 30 weight percent poly(urethane) are prepared by diluting TBAM capped poly(urethane) samples with de-ionized water containing 0.0714 weight percent Irgacure 2959. Quantities of materials are given below.
- Poly(urethane) water solutions are combined and mixed thoroughly.
- the aqueous poly(urethane) solution had a viscosity of 2670 centipoise.
- the aqueous poly(urethane) samples are then frozen and then allowed to thawed two days prior to lens making.
- the poly(urethane) sample is centrifuged at 5000 RPM for 30 minutes and lenses are made in quartz molds under Light Stream manufacturing conditions. The total cure time is 8 seconds.
- NCO terminated poly(urethane) To 14.52 grams of NCO terminated poly(urethane) is added 1.50 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.4 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) To 14.73 grams of NCO terminated poly(urethane) is added 1.31 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.4 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) is added 1.38 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.2 mW/cm2. Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) is added 1.38 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.2 mW/cm2. Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) To 14.85 grams of NCO terminated poly(urethane) is added 1.42 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.2 mW/cm2. Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) To 14.07 grams of NCO terminated poly(urethane) is added 1.39 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.2 mW/cm2. Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) To 14.98 grams of NCO terminated poly(urethane) is added 1.57 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.4 mW/cm2. Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) To 16.17 grams of NCO terminated poly(urethane) is added 1.48 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 15 seconds at 2.4 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 16.
- the stoichiometry of PEG-1000, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:1.0:7.0.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 16.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 16.
- the stoichiometry of PEG-900, pluronic 17R2, TMP, and IPDI is a molar ratio of 3.8:0.2:0.75:6.63.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 16.
- NCO terminated poly(urethane) is added 0.43 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene) molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 10 seconds at 2.5 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) is added 0.41 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 10 seconds at 2.5 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- NCO terminated poly(urethane) is added 0.62 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 10 seconds at 2.5 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- PEG-1450 (40.00 grams), PEEO (2.53 grams) and IPDI (14.34 grams) are combined and heated and stirred at 75° C. under nitrogen until the percentage on NCO in the prepolymer is about 2.42% by weight. The total reaction time for this is about 72 hours.
- NCO terminated poly(urethane) is added 0.61 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene) molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 10 seconds at 2.5 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- PEG-1000 (861.30 grams) and TMP (21.67 grams) are combined and heated at 75° C.
- the resulting melt is dried over 85 grams of 3 angstrom molecular sieves for about 24 hours at 60° C.
- IPDI (316.90 grams) is mixed with to the PEG/TMP melt and the resulting mixture is heated at 60° C. for about one hour.
- the reaction mixture is then decanted away from the melt and stirred at 75° C. under nitrogen until the percentage on NCO in the prepolymer is about 2.12% by weight. The total reaction time for this is about 159 hours.
- NCO terminated poly(urethane) is converted to TBAM capped poly(urethane) in approximately 200 gram portions in 1-liter plastic beakers.
- TBAM capped poly(urethane)
- Samples are mixed thoroughly and then checked by FT-IR. Additional TBAM is added dropwise until NCO is consumed.
- Aqueous solutions containing about 30 weight percent poly(urethane) are prepared by diluting TBAM capped poly(urethane) samples with de-ionized water containing 0.0714 weight percent Irgacure 2959. Quantities of materials are given below.
- Contact lenses are prepared using standard Light Stream conditions with the following exceptions: Cure time is 8 seconds total and lenses are placed in phosphate buffered saline after removal from molds. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 26.
- the stoichiometry of PEG-1000, PEG-300, TMP, and IPDI is a molar ratio of 4:1:1:8.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 26.
- Lenses are prepared according to the procedure described in Example 26.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 27.
- the stoichiometry of PEG-1000, TMP, and IPDI is a molar ratio of 5:1:8.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 27.
- Lenses are prepared according to the procedure described in Example 27.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 26.
- the stoichiometry of PEG-1000, PEG-300, TMP, and IPDI is a molar ratio of 3:2:1:8.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 26.
- Lenses are prepared according to the procedure described in Example 26.
- PEG-1450 (40.00 grams), PEEO (2.53 grams) and IPDI (14.34 grams) are combined and heated and stirred at 75° C. under nitrogen until the percentage on NCO in the prepolymer is about 2.42% by weight. The total reaction time for this is about 72 hours.
- NCO terminated poly(urethane) is added 0.61 grams of TBAM. The resulting mixture is stirred and then checked by FT-IR until NCO is consumed.
- Poly(propylene) molds are filled with about 75 microliters of poly(urethane) solution.
- the poly(urethane) samples are then cured for 10 seconds at 2.5 mW/cm 2 . Molds are opened and lenses are placed in borate buffered saline. Lenses are autoclaved and then characterized to determine physical/mechanical properties according to procedures described in Example 1.
- Isocyanate-capped poly(urethane) is prepared according to the precedure described in Example 34.
- the stoichiometry of PEG-1450, TMP, and IPDI is a molar ratio of 3:1:6.
- Radiation curable prepolymer is prepared by reacting TBAM with the obtained isocayanate-capped poly(urethane) according to a procedure similar to that described in Example 34.
- Tables 1 and 2 summarize the properties of lenses prepared from radiation-curable prepolymers which are obtained by reacting a NCO-capped poly(urethane) with an ethylenically unsaturated group-capping agent (amine or hydroxy compound).
- Example 15 Ethylenical unsaturated Example No. Polyalkylene glycol(s) Branching agent di-isocyanate group capping agent
- Example 15 3.8 PEG-1000 1 TMP 7 IPDI TBAM 1513-63 0.2 Pluronic 17R2
- Example 16 3.6 PEG-1000 1 TMP 7 TMP TBAM 1513-89-1 0.4 Pluronic 17R2
- Example 17 3.6 PEG-1000 0.75 TMP 6.64 IPDI TBAM 1513-89-2 0.4 Pluronic 17R2
- Example 18 3.6 PEG-1000 0.75 TMP 6.64 IPDI TBAM 1513-96-1 0.4 Pluronic L43
- Example 19 3.6 PEG-1000 0.75 TMP 6.64 IPDI TBAM 1513-96-2 0.4 Pluronic L43
- Example 20 3.5 PEG-1000 0.75 TMP 6.63 IPDI TBAM 1525-4 0.25 poly(THF)-650 0.25 Pluronic 17R2
- Example 21 3.75 PEG-1000
Abstract
Description
- (a) at least one polyalkylene glycol of formula
HO—(R1—O)n—(R2—O)m—(R3—O)p—H (1) - wherein R1, R2, and R3, independently of one other, are each linear or branched C2–C4-alkylene, and n, m and p, independently of one another, are each a number from 0 to 100, wherein the sum of (n+m+p) is 5 to 100,
- (b) at least one branching agent selected from the group consisting of
- (i) a linear or branched aliphatic polyhydroxy compound of formula
R4—(OH)x (2), - wherein R4 is a linear or branched C3–C18 aliphatic multi-valent radical and x is a number ≧3,
- (ii) a polyether polyol, which is the polymerization product of a compound of formula (2) and a glycol,
- (iii) a polyester polyol, which is the polymerization product of a compound of formula (2), a dicarboxylic acid or a derivative thereof and a diol, and
- (iv) a cycloaliphatic polyol selected from the group consisting of a C5–C8-cycloalkane which is substituted by ≧3 hydroxy groups and which is unsubstituted by alkyl radical, a C5–C8-cycloalkane which is substituted by ≧3 hydroxy groups and which is substituted by one ore more C1–C4 alkyl radicals, and an unsubstituted mono- and disaccharide,
- (v) an aralkyl polyol having at least three hydroxy C1–C4 alkyl radicals, and
- (i) a linear or branched aliphatic polyhydroxy compound of formula
- (c) at least one di- or polyisocyanate of formula
R5—(NCO)y (3) - wherein R5 a linear or branched aliphatic polyisocyanate with 3 to 24 C-atoms, the radical of a cycloaliphatic or aliphatic-cycloaliphatic polyisocyanate with 3 to 24 C-atoms, or the radical of an aromatic or araliphatic polyisocyanate with 6 to 24 C-atoms, and y is a number from 2 to 6.
In which, I, j and k, independent of one another, are o or 1;
-
- R6 is hydrogen, a linear or branched C1–C24 alkyl, a C2–C24 alkoxyalkyl, a C2–C24 alkylcarbonyl, a C2–C24 alkoxycarbonyl, an unsubstituted or C1–C4 alkyl- or C1–C4 alkoxy-substituted C6–C10 aryl, a C7–C18 aralkyl, a C13–C22 arylalkylaryl, a C3–C8 cycloalkyl, a C4–C14 cycloalkylalkyl, a C7–C18 cycloalkylalkylcycloalkyl, a C5–C20 alkylcycloalkylalkyl, or an aliphatic-heterocyclic radical;
- Z is a C1–C12 alkylene radical, phenylene radical or C7–C12 aralkylene radical;
- R7 and R7′, independently of each other, are hydrogen, C1–C4 alkyl or halogen; and
- Q is an ethylenically unsaturated copolymerizable radical having from 2 to 24 carbon atoms which may be further substituted.
-
- each of R8 and R9 independently of the other is hydrogen, C1–C4 alkyl, phenyl, carboxy or halogen,
- R10 is hydrogen, C1–C4 alkyl or halogen, and
- Z′ is linear or branched C1–C12 alkylene or unsubstituted or C1–C4 alkyl- or C1–C4 alkoxy-substituted phenylene or C7–C12 aralkylene.
- (a) one or more polyalkylene glycols of formula
HO—(CH2—CH2—O)n—(CHY1—CHY2—O)m—H (1a), - wherein one of radicals Y1 and Y2 signifies methyl and the other radical signifies hydrogen,
- and n and m, independently of one another, each denote a number from 0 to 50, wherein the sum of (n+m) is 8 to 50,
- (b) one or more linear or branched aliphatic polyhydroxy compounds of formula
R4—(OH)x (2) - wherein R4 is a linear or branched C3–C18 aliphatic multi-valent radical and x is a number from 3 to 8, and
- (c) one or more diisocyanates of formula
OCN—R5—NCO (3a), - wherein R5 is a linear or branched C3–C18-alkylene, an unsubstituted or C1–C4-alkyl-substituted or C1–C4-alkoxy-substituted C6–C10-arylene, a C7–C18-aralkylene, a C6–C10-arylene-C1–C2-alkylene-C6–C10-arylene, a C3–C8-cyclo-alkylene, a C3–C8-cycloalkylene-C1–C6-alkylene, a C3–C8-cycloalkylene-C1–C2-alkylene-C3–C8cycloalkylene, or a C1–C6-alkylene-C3–C8-cycloalkylene-C1–C6-alkylene.
- (a) at least one poly(ethylene glycol) (i.e., in formula (1a), m is zero.) and at least one hydroxy-terminated poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) or poly(propylene glycol)-poly(ethylene glycol)-poly(propylene glycol) tri-block copolymers,
- (b) one or more linear or branched aliphatic polyhydroxy compounds of formula
R4—(OH)x (2) - wherein R4 is a linear or branched C3–C18 aliphatic multi-valent radical and x is a number from 3 to 8, and
- (c) one or more diisocyanates of formula
OCN—R5—NCO (3a), - wherein R5 is a linear or branched C3–C18-alkylene, an unsubstituted or C1–C4-alkyl-substituted or C1–C4-alkoxy-substituted C6–C10-arylene, a C7–C18-aralkylene, a C6–C10-arylene-C1–C2-alkylene-C6–C10-arylene, a C3–C8-cyclo-alkylene, a C3–C8-cycloalkylene-C1–C6-alkylene, a C3–C8-cycloalkylene-C1–C2-alkylene-C3–C8-cycloalkylene, or a C1–C6-alkylene-C3–C8-cycloalkylene-C1–C6-alkylene.
- (a) one or more polyalkylene glycols of formula
HO—(CH2—CH2—O)n—(CHY1—CHY2—O)m—H (1a), - wherein one of radicals Y1 and Y2 signifies methyl and the other radical signifies hydrogen,
- and n and m, independently of one another, each denote a number from 0 to 25, wherein the sum of (n+m) is 9 to 25,
- (b) one or more polyhydroxy compounds selected from the group consisting of glycerol, diglycerol, triglycerol, 1,1,1-trishydroxymethylethane, 1,1,1-trishydroxymethylpropane, 1,2,4-butanetriol, 1,2,6-hexanetriol, erythritol, pentaerythritol, di- and tripentaerythritol, arabitol, sorbitol, disorbitol and mannitol and mixtures thereof, and
- (c) a diisocyanate of formula
OCN—R5—NCO (3a), - wherein R5 signifies linear or branched C6–C10-alkylene, cyclohexylene-methylene or cyclohexylene-methylene-cyclohexylene either unsubstituted or substituted in the cyclohexyl moiety by 1 to 3 methyl groups, or phenylene or phenylene-methylene-phenylene either unsubstituted or substituted in the phenyl moiety by methyl.
- (a) at least one poly(ethylene glycol) (i.e., in formula (1a), m is zero.) and at least one hydroxy-terminated poly(ethylene glycol)-poly(propylene glycol)-poly(ethylene glycol) or poly(propylene glycol)-poly(ethylene glycol)-poly(propylene glycol) tri-block copolymers,
- (b) one or more polyhydroxy compounds selected from the group consisting of glycerol, diglycerol, triglycerol, 1,1,1-trishydroxymethylethane, 1,1,1-trishydroxymethylpropane, 1,2,4-butanetriol, 1,2,6-hexanetriol, erythritol, pentaerythritol, di- and tripentaerythritol, arabitol, sorbitol, disorbitol and mannitol and mixtures thereof, and
- (c) a diisocyanate of formula
OCN—R5—NCO (3a), - wherein R5 signifies linear or branched C6–C10-alkylene, cyclohexylene-methylene or cyclohexylene-methylene-cyclohexylene either unsubstituted or substituted in the cyclohexyl moiety by 1 to 3 methyl groups, or phenylene or phenylene-methylene-phenylene either unsubstituted or substituted in the phenyl moiety by methyl.
Grams of | Grams of Water | ||
NCO-terminated | Grams of | containing 0.0714 | |
Portion # | Poly(urethan) | TBAM added | percent Irgacure 2959 |
1 | 203.78 | 18.09 | 485.12 |
2 | 203.85 | 18.02 | 485.30 |
3 | 210.70 | 18.70 | 501.54 |
4 | 200.39 | 17.78 | 477.06 |
Grams of | Grams of Water | ||
NCO-terminated | Grams of | containing 0.0714 | |
Portion # | Poly(urethan) | TBAM added | percent Irgacure 2959 |
1 | 208.22 | 19.47 | 531.23 |
2 | 197.48 | 18.47 | 503.87 |
3 | 206.53 | 19.31 | 527.08 |
4 | 208.54 | 19.50 | 532.28 |
Lens Preparation and Testing
TABLE 1A | |||||
Polyalkylene | Branching | Catalyst | Ethylenical Unsaturated | ||
Example No. | glycol(s) | agent | di-isocyanate | DBTDL | Group Capping Agent |
Example 2 | 3.8 PEG-1000 | 1 TMP | 7 IPDI | 0.045 | TBAM |
1525-65 | 0.2 Pluronic | (1525-69) | |||
17R2 | |||||
Example 3 | 3.8 PEG-1000 | 0.75 | 6.63 | 0.045 | TBAM |
1525-66 | 0.2 Pluronic | (1525-71) | |||
17R2 | |||||
Example 4 | 3.8 PEG-1000 | 0.75 | 6.63 | 0.010 | TBAM |
1525-73 | 0.2 Pluronic | (1525-75 | |||
17R2 | |||||
Example 5 | 3.8 PEG-1000 | 0.75 | 6.64 | 0.0050 | HEMA |
1532-13 | 0.2 Pluronic | (1532-15) | |||
See note 3 | 17R2 | ||||
Example 6 | 3.8 PEG-1000 | 0.75 | 6.64 | 0.0050 | HEA |
1532-13 | 0.2 Pluronic | (1532-36) | |||
17R2 | |||||
Example 7 | 3.8 PEG-1000 | 1.0 | 7 | 0.0038 | HEMA |
1532-18 | 0.2 Pluronic | (1532-26) | |||
17R2 | |||||
Example 8 | 3.8 PEG-1000 | 1.0 | 7 | 0.0038 | HEA |
1532-18 | 0.2 Pluronic | (1532-35) | |||
17R2 | |||||
Example 9 | 3.8 PEG-1000 | 1 | 7 | 0.0050 | HEMA |
1532-19 | 0.25 Poly(THF- | (1532-28) | |||
650) | |||||
0.25 Pluronic | |||||
17R2 | |||||
Example 10 | 3.8 PEG-1000 | 1 | 7 | 0.0050 | HEA |
1532-19 | 0.25 Poly(THF- | (1532-34) | |||
650) | |||||
0.25 Pluronic | |||||
17R2 | |||||
Example 11 | 3.8 PEG-1000 | 0.5 | 7 | 0.0109 | HEMA |
1532-54-AQ | 0.2 Pluronic | (1532-54) | |||
non- | 17R2 | ||||
autoclaved | 0.5 ethylene | ||||
glycol | |||||
Example 12 | 3.8 PEG-1000 | 0.75 | 7 | 0.0046 | HEMA |
1532-53-AQ | 0.2 Pluronic | (1532-53) | |||
17R2 | |||||
0.28 ethylene | |||||
glycol | |||||
Example 13 | 3.25 PEG-1000 | 1 | 7 | 0.0057 | HEMA |
1532-58-AQ | 0.25 Pluronic | (1532-58) | |||
17R2 | |||||
0.50 Poly(THF)- | |||||
650 | |||||
Example 14 | Pluronic 17R2 | 0.75 | 6.63 | 0.010 | HEMA |
1532-60-AQ | (1532-59) | ||||
1) TBAM = 2-tert-butylaminoethylmethacrylate, HEMA = 2-hydroxyethylacrylate, HEA = 2-hydroxyethylacrylate | |||||
2) Catalyst amount refers to the relative quantity used during the preparation of NCO capped poly(urethane) prepolymers. Additional catalyst is often used during capping reactions of NCO terminated poly(urethanes) with HEMA and or HEA. |
TABLE 1B | ||||||||
Curing | Curing | |||||||
Time | Intensity | SatB2 | EatB2 | Modulus | H2O | Pin hole | ||
Example | Viscosity1 | (sec) | (mW/cm2) | (N/mm2) | (%) | (N/mm2) | (%) | test |
Example 2 | 3710 | 10 | 2.2 | 1.47 | 809 | 0.44 | 67 | pass |
1525-65 | ||||||||
Example 3 | 2200 | 10 | 2.2 | 1.01 | 854 | 0.28 | 67 | pass |
1525-66 | ||||||||
Example 4 | 2200 | 10 | 2.2 | 1.80 | 1290 | 0.34 | 70.0 | pass |
1525-73 | ||||||||
Example 5 | 444 | 10 | 2.2 | 1.433 | 3663 | 0.443 | 723 | Fail3 |
1532-13 | [1532-16] | 10 | 2.2 | 0.984 | 2834 | 0.364 | 734 | Fail4 |
Example 5 | 444 | 8 | 2.2 | N/A | N/A | N/A | 695a | Fail5a |
1532-13 | [1532-16] | 6 | 2.2 | N/A | N/A | N/A | 685b | Fail5b |
4 | 2.2 | N/A | N/A | N/A | 685c | Pass5c | ||
Example 6 | 615 | 4 | 2.2 | 1.16a | 4436a | 0.346a | 716a | Pass6a |
1532-13 | [1532-42] | 4 | 2.2 | 1.06b | 3896b | 0.336b | 736b | Pass6b |
Example 7 | 391 | 4 | 2.2 | 2.26a | 5166a | 0.546a | 686a | Pass6a |
1532-18 | [1532-31] | 4 | 2.2 | 2.06b | 4456b | 0.596b | 696b | Pass6b |
Example 8 | 291 | 4 | 2.2 | 1.16a | 3446a | 0.386a | 726a | Pass6a |
1532-18 | [1532-41] | 4 | 2.2 | 0.746b | 2206b | 0.356b | 746b | Pass6b |
4 | 2.2 | NA6c | NA6c | NA6c | 726c | Pass6c | ||
Example 9 | 1350 | 4 | 2.2 | 1.46a | 4806a | 0.426a | 696a | Pass6a |
1532-19 | [1532-33] | 4 | 2.2 | 1.46b | 4486b | 0.436b | 696b | Pass6b |
6 | 2.2 | 0.676b | 3796b | 0.226b | 746b | Pass6b | ||
6 | 2.2 | NA6c | NA6c | NA6c | 736c | Pass6c | ||
Example 10 | 1630 | 6 | 2.2 | 0.636a | 3546a | 0.216a | 716a | Fail6a |
1532-19 | [1532-40] | 5 | 2.2 | 2.26c | 6076c | 0.536c | 676c | Pass6c |
5 | 2.2 | 2.26b | 5026b | 0.616b | 656b | Pass6b | ||
Example 11 | 1020 | 5 | 2.2 | 2.27a | 6077a | 0.537a | 677a | Pass7a |
1532-54- | [1532-62] | 5 | 2.2 | 2.27b | 5027b | 0.617b | 657b | Pass7b |
AQ | (40%) | |||||||
Example 12 | 2590 | 5 | 2.2 | 3.57a | 6607a | 0.577a | 687a | Passed7a |
1532-53- | [1532-62] | 5 | 2.2 | 2.37b | 5457b | 0.577b | 687b | Failed7b |
AQ | ||||||||
Example 13 | 54000 | N/A8 | ||||||
1532-58- | ||||||||
AQ | ||||||||
Example 14 | ~8000 | N/A9 | ||||||
1532-60- | [1532-62] | |||||||
AQ | ||||||||
1The viscosity of the aqueous prepolymer solution (30% by weight of the prepolymer unless otherwise stated) for making lenses. | ||||||||
2SatB = Stress at break; EatB = Elongation at beak. | ||||||||
3Autoclaved once prior to testing. | ||||||||
4Lenses are autoclaved twice prior to testing. | ||||||||
5Lenses are all cured at 2.2 mW/cm2 for 8, 6, or 4 seconds and then autoclaved prior to testing | ||||||||
a8 second cure time | ||||||||
b6 second cure time | ||||||||
c4 second cure time | ||||||||
6Lenses are all cured at 2.2 mW/cm2 for 8, 6, or 4 seconds and then autoclaved prior to testing | ||||||||
a4 second cure time, lenses are subjected to one autoclave cycle prior to testing | ||||||||
b4 second cure time, lenses are subjected to two autoclave cycles prior to testing | ||||||||
c4 second cure time, lenses are not autoclaved | ||||||||
7Lenses are cured at 2.2 mW/cm2 for 5 seconds | ||||||||
aNon-autoclaved lenses | ||||||||
bAutoclaved lenses | ||||||||
8The Solution is very viscous and formed cloudy lenses with 69% water content upon UV-Cure. No other measurements are performed. | ||||||||
9Cloud point is near room temperature and no other measurements are made. |
TABLE 2A | ||||
Ethylenical unsaturated | ||||
Example No. | Polyalkylene glycol(s) | Branching agent | di-isocyanate | group capping agent |
Example 15 | 3.8 | PEG-1000 | 1 | TMP | 7 | IPDI | TBAM |
1513-63 | 0.2 | Pluronic 17R2 | |||||
Example 16 | 3.6 | PEG-1000 | 1 | TMP | 7 | TMP | TBAM |
1513-89-1 | 0.4 | Pluronic 17R2 | |||||
Example 17 | 3.6 | PEG-1000 | 0.75 | TMP | 6.64 | IPDI | TBAM |
1513-89-2 | 0.4 | Pluronic 17R2 | |||||
Example 18 | 3.6 | PEG-1000 | 0.75 | TMP | 6.64 | IPDI | TBAM |
1513-96-1 | 0.4 | Pluronic L43 | |||||
Example 19 | 3.6 | PEG-1000 | 0.75 | TMP | 6.64 | IPDI | TBAM |
1513-96-2 | 0.4 | Pluronic L43 | |||||
Example 20 | 3.5 | PEG-1000 | 0.75 | TMP | 6.63 | IPDI | TBAM |
1525-4 | 0.25 | poly(THF)-650 | |||||
0.25 | Pluronic 17R2 | ||||||
Example 21 | 3.75 | PEG-1000 | 0.75 | TMP | 6.62 | IPDI | TBAM |
1525-6 | 0.25 | poly(THF)-650 | |||||
Example 22 | 3.25 | PEG-1000 | 0.75 | TMP | 6.63 | IPDI | TBAM |
1525-30 | 0.5 | poly(THF)-650 | |||||
0.25 | Pluronic 17R2 | ||||||
Example 23 | 3.55 | PEG-1000 | 0.75 | TMP | 6.63 | IPDI | TBAM |
1525-36 | 0.25 | Pluronic 17R2 | |||||
0.25 | 3,3-DM-1,2-BD | ||||||
Example 24 | 3.8 | PEG-1000 | 1 | TMP | 7 | IPDI | TBAM |
1513-63 | 0.2 | Pluronic 17R2 | |||||
Example 25 | 3.8 | PEG-900 | 0.75 | TMP | 6.63 | IPDI | TBAM |
1525-38 | 0.2 | Pluronic 17R2 | |||||
Example 26 | 4 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-48 | 1 | PEG-300 | |||||
Example 27 | 5 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-49 | |||||||
Example 28 | 3 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-57 | 2 | PEG-300 | |||||
Example 29 | 3 | PEG-1450 | 1 | PEEO | 7 | IPDI | TBAM |
1310-25 | 1 | PEG-300 | |||||
Example 30 | 4 | PEG-1000 | 0.75 | TMP | 6.62 | IPDI | TBAM |
1513-59 | |||||||
Example 31 | 4 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-48 | 1 | PEG-300 | |||||
Example 32 | 5 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-49 | |||||||
Example 33 | 3 | PEG-1000 | 1 | TMP | 8 | IPDI | TBAM |
1310-57 | 2 | PEG-300 | |||||
Example 34 | 3 | PEG-1450 | 1 | PEEO | 7 | IPDI | TBAM |
1310-25 | |||||||
Example 35 | 3 | PEG-1450 | 1 | TMP | 6 | IPDI | TBAM |
1302-20-C | |||||||
TABLE 2B | ||||||
Example | Stress at break | Elongation | Modulus | H2O | ||
No. | Viscosity | (N/mm2) | at beak (%) | (N/mm2) | (%) | Pin hole test |
Example 15 | 2670 | 0.79 | 1002 (>476) | 0.28 | 71 | pass |
1513-63 | 1.2 | 1047 | 0.12 | |||
0.87 | 0.11 | |||||
Example 16 | 1030 | 0.53 | 1221 | 0.06 | 76 | |
1513-89-1 | ||||||
Example 17 | 1320 | 0.74 | 1404 | 0.09 | 76 | pass |
1513-89-2 | ||||||
Example 18 | 1060 | 0.67 | 1574 | 0.10 | 75 | pass |
1513-96-1 | ||||||
Example 19 | 2780 | 0.57 | 1360 | 0.10 | 76 | pass |
1513-96-2 | ||||||
Example 20 | 1510 | 0.54 | 1411 | 0.07 | 76 | pass |
1525-4 | ||||||
Example 21 | 862 | 0.36 | 1419 | 0.03 | 79 | pass |
1525-6 | ||||||
Example 22 | 3610 | 0.54 | 1419 | 0.11 | 73 | pass |
1525-30 | ||||||
Example 23 | 1200 | 0.84 | 1725 | 0.04 | 75 | pass |
1525-36 | ||||||
Example 24 | 2670 | 1.4 | 1283 | 0.18 | 70 | pass |
1513-63 | ||||||
Example 25 | 1200 | 0.81 | 1229 | 0.11 | 72 | pass |
1525-38 | ||||||
Example 26 | 1990 | 0.6 | 1512 | 0.08 | 75 | |
1310-48 | ||||||
Example 27 | 1120 | 0.43 | 1296 | 0.05 | 80 | |
1310-49 | ||||||
Example 28 | 2450 | 0.58 | 1237 | 0.06 | 73 | |
1310-57 | ||||||
Example 29 | 71500 | 0.63 | 500 | 0.21 | 77 | |
1310-25 | ||||||
Example 30 | 1400 | 0.62 | 1213 | 0.15 | 71 | |
1513-59 | ||||||
Example 31 | 1990 | 0.6 | 1512 | 0.08 | 75 | |
1310-48 | ||||||
Example 32 | 1120 | 0.43 | 1296 | 0.05 | 80 | |
1310-49 | ||||||
Example 33 | 2450 | 0.58 | 1237 | 0.06 | 73 | |
1310-57 | ||||||
Example 34 | 71500 | 0.63 | 500 | 0.21 | 77 | |
1310-25 | ||||||
Example 35 | 2640 | 0.6 | 623 | 0.11 | 79 | |
1302-20-C | ||||||
Claims (22)
HO—(R1—O)n—(R2—O)m—(R3—O)p—H (1)
R4—(OH)x (2),
R5—(NCO)y (3)
OCN—R5—NCO (3a)
OCN—R5—NCO (3a),
R4—(OH)x (2)
OCN—R5—NCO (3a),
OCN—R5—NCO (3a)
OCN—R5—NCO (3a),
HO—(R1—O)n—(R2—O)m—H (1′)
R4—(OH)x (2),
R5—(NCO)y (3)
OCN—R5—NCO (3a)
OCN—R5—NCO (3a),
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/640,294 US6995192B2 (en) | 2002-08-14 | 2003-08-13 | Radiation-curable prepolymers |
US11/243,928 US7279505B2 (en) | 2002-08-14 | 2005-10-05 | Radiation-curable prepolymers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40333302P | 2002-08-14 | 2002-08-14 | |
US10/640,294 US6995192B2 (en) | 2002-08-14 | 2003-08-13 | Radiation-curable prepolymers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/243,928 Division US7279505B2 (en) | 2002-08-14 | 2005-10-05 | Radiation-curable prepolymers |
Publications (2)
Publication Number | Publication Date |
---|---|
US20040082680A1 US20040082680A1 (en) | 2004-04-29 |
US6995192B2 true US6995192B2 (en) | 2006-02-07 |
Family
ID=31888226
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/640,294 Expired - Lifetime US6995192B2 (en) | 2002-08-14 | 2003-08-13 | Radiation-curable prepolymers |
US11/243,928 Expired - Lifetime US7279505B2 (en) | 2002-08-14 | 2005-10-05 | Radiation-curable prepolymers |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/243,928 Expired - Lifetime US7279505B2 (en) | 2002-08-14 | 2005-10-05 | Radiation-curable prepolymers |
Country Status (6)
Country | Link |
---|---|
US (2) | US6995192B2 (en) |
EP (1) | EP1534767B1 (en) |
JP (1) | JP4751067B2 (en) |
AU (1) | AU2003258609A1 (en) |
DE (1) | DE60317797T2 (en) |
WO (1) | WO2004016671A1 (en) |
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060149017A1 (en) * | 2002-08-31 | 2006-07-06 | Ocutec Limited | Novel thermoplastic hydrogel polymer cmpositions for use in producing contact lenses and methods of proucing said compositions |
US20060251696A1 (en) * | 2005-05-05 | 2006-11-09 | Winterton Lynn C | Ophthalmic devices for sustained delivery of active compounds |
US20080015315A1 (en) * | 2006-07-12 | 2008-01-17 | Frank Chang | Novel Polymers |
US20080143958A1 (en) * | 2006-12-13 | 2008-06-19 | Arturo Norberto Medina | Production of ophthalmic devices based on photo-induced step growth polymerization |
US20080174035A1 (en) * | 2006-06-08 | 2008-07-24 | Lynn Cook Winterton | Silicone hydrogel contact lenses |
US20100140114A1 (en) * | 2008-12-05 | 2010-06-10 | John Dallas Pruitt | Ophthalmic devices for delivery of hydrophobic comfort agents |
US20100296049A1 (en) * | 2009-05-22 | 2010-11-25 | Justyna Justynska | Actinically-crosslinkable siloxane-containing copolymers |
US20100298446A1 (en) * | 2009-05-22 | 2010-11-25 | Frank Chang | Actinically-crosslinkable siloxane-containing copolymers |
US8431624B2 (en) | 2009-09-15 | 2013-04-30 | Novartis Ag | Prepolymers suitable for making ultra-violet absorbing contact lenses |
US8557940B2 (en) | 2010-07-30 | 2013-10-15 | Novartis Ag | Amphiphilic polysiloxane prepolymers and uses thereof |
US8835525B2 (en) | 2010-10-06 | 2014-09-16 | Novartis Ag | Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains |
US8993651B2 (en) | 2010-10-06 | 2015-03-31 | Novartis Ag | Polymerizable chain-extended polysiloxanes with pendant hydrophilic groups |
US9000065B2 (en) | 2009-11-06 | 2015-04-07 | Ocutec Ltd. | Polymers for contact lenses |
US9187601B2 (en) | 2010-10-06 | 2015-11-17 | Novartis Ag | Water-processable silicone-containing prepolymers and uses thereof |
US9243102B2 (en) | 2009-11-05 | 2016-01-26 | Ocutec Limited | Polymers for contact lenses |
WO2016145204A1 (en) | 2015-03-11 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Mesh size control of lubrication in gemini hydrogels |
US9464159B2 (en) | 2009-11-02 | 2016-10-11 | Ocutec Limited | Polymers for contact lenses |
WO2017093834A1 (en) | 2015-12-03 | 2017-06-08 | Novartis Ag | Contact lens packaging solutions |
WO2017145022A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv/visible-absorbing vinylic monomers and uses thereof |
WO2017145024A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv-absorbing vinylic monomers and uses thereof |
US10081142B2 (en) | 2015-12-15 | 2018-09-25 | Novartis Ag | Method for producing contact lenses with a lubricious surface |
WO2019043577A1 (en) | 2017-08-29 | 2019-03-07 | Novartis Ag | Cast-molding process for producing contact lenses |
WO2019116142A1 (en) | 2017-12-13 | 2019-06-20 | Novartis Ag | Method for producing mps-compatible water gradient contact lenses |
WO2019142132A1 (en) | 2018-01-22 | 2019-07-25 | Novartis Ag | Cast-molding process for producing uv-absorbing contact lenses |
WO2020100090A1 (en) | 2018-11-15 | 2020-05-22 | Alcon Inc. | Contact lens with phosphorylcholine-modified polyvinylalcohols therein |
WO2020208576A1 (en) | 2019-04-10 | 2020-10-15 | Alcon Inc. | Method for producing coated contact lenses |
US10809181B2 (en) | 2017-08-24 | 2020-10-20 | Alcon Inc. | Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens |
WO2020240442A1 (en) | 2019-05-28 | 2020-12-03 | Alcon Inc. | Pad transfer printing instrument and method for making colored contact lenses |
WO2022097049A1 (en) | 2020-11-04 | 2022-05-12 | Alcon Inc. | Method for making photochromic contact lenses |
WO2022097048A1 (en) | 2020-11-04 | 2022-05-12 | Alcon Inc. | Method for making photochromic contact lenses |
WO2022189940A1 (en) | 2021-03-08 | 2022-09-15 | Alcon Inc. | Method for making photofunctional contact lenses |
WO2022201072A1 (en) | 2021-03-24 | 2022-09-29 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2022208447A1 (en) | 2021-04-01 | 2022-10-06 | Alcon Inc. | Embedded hydrogel contact lenses |
WO2022208448A1 (en) | 2021-04-01 | 2022-10-06 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023209570A1 (en) | 2022-04-26 | 2023-11-02 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023209569A1 (en) | 2022-04-26 | 2023-11-02 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023218324A1 (en) | 2022-05-09 | 2023-11-16 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023228106A1 (en) | 2022-05-25 | 2023-11-30 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023228055A1 (en) | 2022-05-23 | 2023-11-30 | Alcon Inc. | Uv/hevl-filtering contact lenses |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8147728B2 (en) | 2004-04-01 | 2012-04-03 | Novartis Ag | Pad transfer printing of silicone hydrogel lenses using colored ink |
US7795359B2 (en) | 2005-03-04 | 2010-09-14 | Novartis Ag | Continuous process for production of polymeric materials |
EP2094235A2 (en) * | 2006-11-06 | 2009-09-02 | Novartis AG | Ocular devices and methods of making and using thereof |
MX2009010116A (en) | 2007-03-22 | 2009-10-12 | Novartis Ag | Prepolymers with dangling polysiloxane-containing polymer chains. |
TWI419719B (en) | 2007-08-31 | 2013-12-21 | Novartis Ag | Contact lens products |
RU2488863C2 (en) | 2007-12-20 | 2013-07-27 | Новартис Аг | Method of making contact lenses |
US8408697B2 (en) * | 2008-03-07 | 2013-04-02 | Paragon Vision Sciences, Inc. | High refractive index oxygen permeable contact lens system and method |
RU2544540C2 (en) | 2008-12-30 | 2015-03-20 | Новартис Аг | Trifunctional compounds absorbing uv-radiation and application thereof |
US8292625B2 (en) | 2010-07-23 | 2012-10-23 | Pulpdent Corporation | Radically curable urethane dimethacrylates and compositions thereof for tougher dental prosthetics |
EP2638878B1 (en) | 2010-07-30 | 2019-10-23 | Novartis AG | Silicone hydrogel lenses with water-rich surfaces |
EP2637847B1 (en) | 2010-11-10 | 2014-07-23 | Novartis AG | Method for making contact lenses |
EP2652532B1 (en) | 2010-12-13 | 2016-06-08 | Novartis AG | Ophthalmic lenses modified with functional groups and methods of making thereof |
JP5808971B2 (en) * | 2011-07-22 | 2015-11-10 | 株式会社Adeka | Water-based polyurethane resin composition, easy-adhesive polyester film formed by applying this |
EP2931732B1 (en) | 2012-12-14 | 2020-11-25 | Alcon Inc. | Amphiphilic siloxane-containing vinylic monomers and uses thereof |
JP6154022B2 (en) | 2012-12-14 | 2017-06-28 | ノバルティス アーゲー | Amphiphilic siloxane-containing (meth) acrylamides and their use |
JP6034982B2 (en) | 2012-12-14 | 2016-11-30 | ノバルティス アーゲー | Actinic crosslinkable amphiphilic prepolymer |
EP2931733B1 (en) | 2012-12-14 | 2016-10-05 | Novartis AG | Tris(trimethyl siloxy)silane vinylic monomers and uses thereof |
EP3062979B1 (en) | 2013-10-31 | 2018-08-29 | Novartis AG | Method for producing ophthalmic lenses |
CN105793022B (en) | 2013-12-13 | 2017-09-19 | 诺华股份有限公司 | Method for preparing haptic lens |
EP3134420B1 (en) | 2014-04-25 | 2019-01-30 | Novartis AG | Carbosiloxane vinylic monomers |
CA2940207C (en) | 2014-04-25 | 2019-09-10 | Novartis Ag | Hydrophilized carbosiloxane vinylic monomers |
WO2016032926A1 (en) | 2014-08-26 | 2016-03-03 | Novartis Ag | Method for applying stable coating on silicone hydrogel contact lenses |
US10160141B2 (en) | 2014-11-25 | 2018-12-25 | Novartis Ag | Molds for making contact lenses |
EP3303415B1 (en) | 2015-06-02 | 2022-12-28 | Alcon Inc. | Visible-light photoinitiators and uses thereof |
WO2017083321A1 (en) * | 2015-11-10 | 2017-05-18 | Sun Chemical Corporation | Alkoxylated dispersing agents |
CN108369291B (en) | 2015-12-15 | 2021-07-20 | 爱尔康公司 | Method for applying a stable coating on a silicone hydrogel contact lens |
CN105404095A (en) * | 2015-12-23 | 2016-03-16 | 河南工程学院 | Washable ultraviolet laser curing and rapid prototyping photosensitive resin and preparation method thereof |
WO2021133585A1 (en) | 2019-12-23 | 2021-07-01 | Carbon, Inc. | Inhibition of crystallization in polyurethane resins |
US11859057B2 (en) | 2020-03-12 | 2024-01-02 | Carbon, Inc. | Partially reversible thermosets useful for recycling |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4065587A (en) * | 1976-05-11 | 1977-12-27 | Scm Corporation | U.V. Curable poly(ether-urethane) polyacrylates and wet-look polymers prepared therefrom |
US5508317A (en) | 1993-08-06 | 1996-04-16 | Ciba-Geigy Corporation | Photocrosslinked polymers |
US5665840A (en) | 1994-11-18 | 1997-09-09 | Novartis Corporation | Polymeric networks from water-soluble prepolymers |
US5807927A (en) | 1995-02-03 | 1998-09-15 | Ciba Vision Corporation | Crosslinked polymers containing urethane groups |
US5849841A (en) | 1995-02-03 | 1998-12-15 | Ciba Vision Corporation | Crosslinked polymers containing ester or amide groups |
US5872675A (en) | 1997-01-21 | 1999-02-16 | Tandberg Data Asa | Tape cartridge with integrated mirror tracking mechanism |
US5932674A (en) | 1995-02-03 | 1999-08-03 | Novartis Ag | Crosslinked polymers |
US5936052A (en) | 1993-11-26 | 1999-08-10 | Ciba Vision Corporation | Cross-linkable copolymers and hydrogels |
US5939489A (en) | 1995-02-03 | 1999-08-17 | Novartis Ag | Crosslinked polymers containing salt structures |
US6011077A (en) | 1995-02-03 | 2000-01-04 | Novartis Ag | Crosslinkable polymers containing bonded photoinitiators |
US6106746A (en) | 1996-07-26 | 2000-08-22 | Novartis Ag | Manufacture of mouldings |
US6149842A (en) | 1998-11-12 | 2000-11-21 | Novartis Ag | Methods and compositions for manufacturing tinted ophthalmic lenses |
US6149692A (en) | 1998-08-27 | 2000-11-21 | Novartis Ag | Method and composition for incorporating radiation-absorbing agents into polymers |
US6156244A (en) | 1996-05-23 | 2000-12-05 | Novartis Ag | Storage-stable hydrogels |
US6162844A (en) | 1996-08-01 | 2000-12-19 | Novartis Ag | Method and composition for incorporating radiation-absorbing agents into polymers |
US6190603B1 (en) | 1997-07-19 | 2001-02-20 | Novartis Ag | Process for producing mouldings |
US6265509B1 (en) | 1997-07-30 | 2001-07-24 | Novartis Ag | Crosslinked polymers |
US6342570B1 (en) | 1994-11-14 | 2002-01-29 | Novartis Ag | Cross-linkable copolymers and hydrogels |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5020972B2 (en) * | 1971-09-29 | 1975-07-18 | ||
US5034461A (en) * | 1989-06-07 | 1991-07-23 | Bausch & Lomb Incorporated | Novel prepolymers useful in biomedical devices |
DE4027804A1 (en) * | 1990-09-01 | 1992-03-05 | Abb Patent Gmbh | Measurement method using multimeter protected against over voltge - measuring one or more voltages and determining whether to switch to lower range |
TW425403B (en) * | 1997-02-04 | 2001-03-11 | Novartis Ag | Branched polyurethane (meth)acrylate prepolymers, opthal-mic mouldings derived therefrom and processes for their manufacture |
EP0867456A1 (en) * | 1997-02-04 | 1998-09-30 | Novartis AG | Ophthalmic moulded part |
ES2175698T3 (en) * | 1997-02-21 | 2002-11-16 | Novartis Ag | OPTIONAL MOLDING ITEMS. |
-
2003
- 2003-08-13 DE DE60317797T patent/DE60317797T2/en not_active Expired - Lifetime
- 2003-08-13 AU AU2003258609A patent/AU2003258609A1/en not_active Abandoned
- 2003-08-13 JP JP2004528489A patent/JP4751067B2/en not_active Expired - Fee Related
- 2003-08-13 US US10/640,294 patent/US6995192B2/en not_active Expired - Lifetime
- 2003-08-13 WO PCT/EP2003/009002 patent/WO2004016671A1/en active IP Right Grant
- 2003-08-13 EP EP03787788A patent/EP1534767B1/en not_active Expired - Lifetime
-
2005
- 2005-10-05 US US11/243,928 patent/US7279505B2/en not_active Expired - Lifetime
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4065587A (en) * | 1976-05-11 | 1977-12-27 | Scm Corporation | U.V. Curable poly(ether-urethane) polyacrylates and wet-look polymers prepared therefrom |
US5508317A (en) | 1993-08-06 | 1996-04-16 | Ciba-Geigy Corporation | Photocrosslinked polymers |
US5583163A (en) | 1993-08-06 | 1996-12-10 | Ciba Geigy Corporation | Photocrosslinked polymers |
US5789464A (en) | 1993-08-06 | 1998-08-04 | Ciba Vision Corporation | Photocrosslinked polymers |
US5849810A (en) | 1993-08-06 | 1998-12-15 | Ciba Vision Corporation | Photocrosslinked polymers |
US5936052A (en) | 1993-11-26 | 1999-08-10 | Ciba Vision Corporation | Cross-linkable copolymers and hydrogels |
US6342570B1 (en) | 1994-11-14 | 2002-01-29 | Novartis Ag | Cross-linkable copolymers and hydrogels |
US5665840A (en) | 1994-11-18 | 1997-09-09 | Novartis Corporation | Polymeric networks from water-soluble prepolymers |
US5807927A (en) | 1995-02-03 | 1998-09-15 | Ciba Vision Corporation | Crosslinked polymers containing urethane groups |
US5932674A (en) | 1995-02-03 | 1999-08-03 | Novartis Ag | Crosslinked polymers |
US5939489A (en) | 1995-02-03 | 1999-08-17 | Novartis Ag | Crosslinked polymers containing salt structures |
US6011077A (en) | 1995-02-03 | 2000-01-04 | Novartis Ag | Crosslinkable polymers containing bonded photoinitiators |
US5849841A (en) | 1995-02-03 | 1998-12-15 | Ciba Vision Corporation | Crosslinked polymers containing ester or amide groups |
US6303687B1 (en) | 1995-02-03 | 2001-10-16 | Novartis Ag | Crosslinked polymers containing salt structures |
US6156244A (en) | 1996-05-23 | 2000-12-05 | Novartis Ag | Storage-stable hydrogels |
US6106746A (en) | 1996-07-26 | 2000-08-22 | Novartis Ag | Manufacture of mouldings |
US6162844A (en) | 1996-08-01 | 2000-12-19 | Novartis Ag | Method and composition for incorporating radiation-absorbing agents into polymers |
US5872675A (en) | 1997-01-21 | 1999-02-16 | Tandberg Data Asa | Tape cartridge with integrated mirror tracking mechanism |
US6190603B1 (en) | 1997-07-19 | 2001-02-20 | Novartis Ag | Process for producing mouldings |
US6265509B1 (en) | 1997-07-30 | 2001-07-24 | Novartis Ag | Crosslinked polymers |
US6149692A (en) | 1998-08-27 | 2000-11-21 | Novartis Ag | Method and composition for incorporating radiation-absorbing agents into polymers |
US6149842A (en) | 1998-11-12 | 2000-11-21 | Novartis Ag | Methods and compositions for manufacturing tinted ophthalmic lenses |
Cited By (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100063240A1 (en) * | 2002-08-31 | 2010-03-11 | Ocutec Limited | Novel Thermoplastic Hydrogel Polymer Compositions For Use In Producing Contact Lenses And Methods Of Producing Said Compositions |
US20060149017A1 (en) * | 2002-08-31 | 2006-07-06 | Ocutec Limited | Novel thermoplastic hydrogel polymer cmpositions for use in producing contact lenses and methods of proucing said compositions |
US20060251696A1 (en) * | 2005-05-05 | 2006-11-09 | Winterton Lynn C | Ophthalmic devices for sustained delivery of active compounds |
US9804295B2 (en) | 2005-05-05 | 2017-10-31 | Novartis Ag | Ophthalmic devices for sustained delivery of active compounds |
US7858000B2 (en) | 2006-06-08 | 2010-12-28 | Novartis Ag | Method of making silicone hydrogel contact lenses |
US20080174035A1 (en) * | 2006-06-08 | 2008-07-24 | Lynn Cook Winterton | Silicone hydrogel contact lenses |
US20080015315A1 (en) * | 2006-07-12 | 2008-01-17 | Frank Chang | Novel Polymers |
US8703875B2 (en) | 2006-07-12 | 2014-04-22 | Novartis Ag | Polymers |
US8404783B2 (en) | 2006-07-12 | 2013-03-26 | Novartis Ag | Polymers |
US20080143958A1 (en) * | 2006-12-13 | 2008-06-19 | Arturo Norberto Medina | Production of ophthalmic devices based on photo-induced step growth polymerization |
US8003710B2 (en) | 2006-12-13 | 2011-08-23 | Novartis Ag | Production of ophthalmic devices based on photo-induced step growth polymerization |
US8357771B2 (en) | 2006-12-13 | 2013-01-22 | Novartis Ag | Production of ophthalmic devices based on photo-induced step growth polymerization |
US8609745B2 (en) | 2006-12-13 | 2013-12-17 | Novartis Ag | Production of ophthalmic devices based on photo-induced step growth polymerization |
US10155349B2 (en) | 2008-12-05 | 2018-12-18 | Novartis Ag | Ophthalmic devices for delivery of hydrophobic comfort agents |
US20100140114A1 (en) * | 2008-12-05 | 2010-06-10 | John Dallas Pruitt | Ophthalmic devices for delivery of hydrophobic comfort agents |
US20100298446A1 (en) * | 2009-05-22 | 2010-11-25 | Frank Chang | Actinically-crosslinkable siloxane-containing copolymers |
US9066981B2 (en) | 2009-05-22 | 2015-06-30 | Novartis Ag | Actinically-crosslinkable siloxane-containing copolymers |
US8642712B2 (en) | 2009-05-22 | 2014-02-04 | Novartis Ag | Actinically-crosslinkable siloxane-containing copolymers |
US20100296049A1 (en) * | 2009-05-22 | 2010-11-25 | Justyna Justynska | Actinically-crosslinkable siloxane-containing copolymers |
US8383744B2 (en) | 2009-05-22 | 2013-02-26 | Novartis Ag | Actinically-crosslinkable siloxane-containing copolymers |
US8431624B2 (en) | 2009-09-15 | 2013-04-30 | Novartis Ag | Prepolymers suitable for making ultra-violet absorbing contact lenses |
US9464159B2 (en) | 2009-11-02 | 2016-10-11 | Ocutec Limited | Polymers for contact lenses |
US9243102B2 (en) | 2009-11-05 | 2016-01-26 | Ocutec Limited | Polymers for contact lenses |
US9000065B2 (en) | 2009-11-06 | 2015-04-07 | Ocutec Ltd. | Polymers for contact lenses |
US8987403B2 (en) | 2010-07-30 | 2015-03-24 | Novartis Ag | Amphiphilic polysiloxane prepolymers and uses thereof |
US9341744B2 (en) | 2010-07-30 | 2016-05-17 | Novartis Ag | Amphiphilic polysiloxane prepolymers and uses thereof |
US8557940B2 (en) | 2010-07-30 | 2013-10-15 | Novartis Ag | Amphiphilic polysiloxane prepolymers and uses thereof |
US9109091B2 (en) | 2010-10-06 | 2015-08-18 | Novartis Ag | Polymerizable chain-extended polysiloxanes with pendant hydrophilic groups |
US9187601B2 (en) | 2010-10-06 | 2015-11-17 | Novartis Ag | Water-processable silicone-containing prepolymers and uses thereof |
US9052440B2 (en) | 2010-10-06 | 2015-06-09 | Novartis Ag | Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains |
US8993651B2 (en) | 2010-10-06 | 2015-03-31 | Novartis Ag | Polymerizable chain-extended polysiloxanes with pendant hydrophilic groups |
US9921340B2 (en) | 2010-10-06 | 2018-03-20 | Novartis Ag | Water-processable silicone-containing prepolymers and uses thereof |
US8835525B2 (en) | 2010-10-06 | 2014-09-16 | Novartis Ag | Chain-extended polysiloxane crosslinkers with dangling hydrophilic polymer chains |
WO2016145204A1 (en) | 2015-03-11 | 2016-09-15 | University Of Florida Research Foundation, Inc. | Mesh size control of lubrication in gemini hydrogels |
US10723842B2 (en) | 2015-03-11 | 2020-07-28 | University Of Florida Research Foundation, Inc. | Mesh size control of lubrication in gemini hydrogels |
US9829723B2 (en) | 2015-12-03 | 2017-11-28 | Novartis Ag | Contact lens packaging solutions |
EP3543004A1 (en) | 2015-12-03 | 2019-09-25 | Novartis AG | Contact lens packaging solutions |
WO2017093834A1 (en) | 2015-12-03 | 2017-06-08 | Novartis Ag | Contact lens packaging solutions |
US10081142B2 (en) | 2015-12-15 | 2018-09-25 | Novartis Ag | Method for producing contact lenses with a lubricious surface |
WO2017145022A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv/visible-absorbing vinylic monomers and uses thereof |
US10254567B2 (en) | 2016-02-22 | 2019-04-09 | Novartis Ag | UV-absorbing vinylic monomers and uses thereof |
US10268053B2 (en) | 2016-02-22 | 2019-04-23 | Novartis Ag | UV/visible-absorbing vinylic monomers and uses thereof |
WO2017145024A1 (en) | 2016-02-22 | 2017-08-31 | Novartis Ag | Uv-absorbing vinylic monomers and uses thereof |
US10809181B2 (en) | 2017-08-24 | 2020-10-20 | Alcon Inc. | Method and apparatus for determining a coefficient of friction at a test site on a surface of a contact lens |
WO2019043577A1 (en) | 2017-08-29 | 2019-03-07 | Novartis Ag | Cast-molding process for producing contact lenses |
US10906258B2 (en) | 2017-08-29 | 2021-02-02 | Alcon Inc. | Cast-molding process for producing contact lenses |
WO2019116140A1 (en) | 2017-12-13 | 2019-06-20 | Novartis Ag | Method for producing mps-compatible water gradient contact lenses |
WO2019116139A1 (en) | 2017-12-13 | 2019-06-20 | Novartis Ag | Weekly and monthly disposable water gradient contact lenses |
WO2019116141A1 (en) | 2017-12-13 | 2019-06-20 | Novartis Ag | Method for producing mps-compatible water gradient contact lenses |
US10830923B2 (en) | 2017-12-13 | 2020-11-10 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11256003B2 (en) | 2017-12-13 | 2022-02-22 | Alcon Inc. | Weekly and monthly disposable water gradient contact lenses |
WO2019116142A1 (en) | 2017-12-13 | 2019-06-20 | Novartis Ag | Method for producing mps-compatible water gradient contact lenses |
US11029447B2 (en) | 2017-12-13 | 2021-06-08 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11029446B2 (en) | 2017-12-13 | 2021-06-08 | Alcon Inc. | Method for producing MPS-compatible water gradient contact lenses |
US11111327B2 (en) | 2018-01-22 | 2021-09-07 | Alcon Inc. | Cast-molding process for producing UV-absorbing contact lenses |
WO2019142132A1 (en) | 2018-01-22 | 2019-07-25 | Novartis Ag | Cast-molding process for producing uv-absorbing contact lenses |
WO2020100090A1 (en) | 2018-11-15 | 2020-05-22 | Alcon Inc. | Contact lens with phosphorylcholine-modified polyvinylalcohols therein |
US11061169B2 (en) | 2018-11-15 | 2021-07-13 | Alcon Inc. | Contact lens with phosphorylcholine-modified polyvinylalcohols therein |
US11648583B2 (en) | 2019-04-10 | 2023-05-16 | Alcon Inc. | Method for producing coated contact lenses |
WO2020208576A1 (en) | 2019-04-10 | 2020-10-15 | Alcon Inc. | Method for producing coated contact lenses |
US11602910B2 (en) | 2019-05-28 | 2023-03-14 | Alcon Inc. | Pad transfer printing method for making colored contact lenses |
WO2020240442A1 (en) | 2019-05-28 | 2020-12-03 | Alcon Inc. | Pad transfer printing instrument and method for making colored contact lenses |
WO2022097049A1 (en) | 2020-11-04 | 2022-05-12 | Alcon Inc. | Method for making photochromic contact lenses |
WO2022097048A1 (en) | 2020-11-04 | 2022-05-12 | Alcon Inc. | Method for making photochromic contact lenses |
US11886045B2 (en) | 2020-11-04 | 2024-01-30 | Alcon Inc. | Method for making photochromic contact lenses |
WO2022189941A1 (en) | 2021-03-08 | 2022-09-15 | Alcon Inc. | Method for making photochromic contact lenses |
WO2022189940A1 (en) | 2021-03-08 | 2022-09-15 | Alcon Inc. | Method for making photofunctional contact lenses |
WO2022201072A1 (en) | 2021-03-24 | 2022-09-29 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2022208448A1 (en) | 2021-04-01 | 2022-10-06 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2022208447A1 (en) | 2021-04-01 | 2022-10-06 | Alcon Inc. | Embedded hydrogel contact lenses |
WO2023209570A1 (en) | 2022-04-26 | 2023-11-02 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023209569A1 (en) | 2022-04-26 | 2023-11-02 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023218324A1 (en) | 2022-05-09 | 2023-11-16 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
WO2023228055A1 (en) | 2022-05-23 | 2023-11-30 | Alcon Inc. | Uv/hevl-filtering contact lenses |
WO2023228106A1 (en) | 2022-05-25 | 2023-11-30 | Alcon Inc. | Method for making embedded hydrogel contact lenses |
Also Published As
Publication number | Publication date |
---|---|
US20040082680A1 (en) | 2004-04-29 |
JP2005535757A (en) | 2005-11-24 |
US7279505B2 (en) | 2007-10-09 |
WO2004016671A1 (en) | 2004-02-26 |
DE60317797D1 (en) | 2008-01-10 |
DE60317797T2 (en) | 2008-10-30 |
EP1534767A1 (en) | 2005-06-01 |
EP1534767B1 (en) | 2007-11-28 |
AU2003258609A1 (en) | 2004-03-03 |
US20060030679A1 (en) | 2006-02-09 |
JP4751067B2 (en) | 2011-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6995192B2 (en) | Radiation-curable prepolymers | |
US7888426B2 (en) | Polymerizable materials | |
US7977430B2 (en) | Crosslinkable polyurea prepolymers | |
JP4098367B2 (en) | Molded product for eye | |
US6221303B1 (en) | Ophthalmic mouldings | |
JP3145793B2 (en) | High oxygen permeability ophthalmic soft lens | |
EP0958315B1 (en) | Moulded ophthalmic article | |
EP0832142B1 (en) | Polymerizable siloxane macromonomers | |
AU704749B2 (en) | Extended wear ophthalmic lens | |
EP1838748B1 (en) | Polysiloxane prepolymers for biomedical devices | |
US4929692A (en) | Crosslinked copolymers and ophthalmic devices made from vinylic macromers containing perfluoropolyalkyl ether and polyalkyl ether segments and minor amounts of vinylic comonomers | |
JP3059183B2 (en) | Vinyl-based polymer, polymer, copolymer containing perfluoropolyalkyl ether and polyalkyl ether segment, and ophthalmic device produced therefrom | |
US20070105973A1 (en) | Extended Wear Ophthalmic Lens | |
EP1873180B1 (en) | Ophthalmic device made from a radiation-curable prepolymer | |
EP0084406A1 (en) | Ophthalmic device comprising a polymer of a telechelic perfluoropolyether | |
WO2006132842A2 (en) | Method for making biomedical devices | |
US4933408A (en) | Vinylic macromers containing perfluoropolyalkyl ether and polyalkyl ether segments, polymers and opthalmic devices made therefrom | |
US5075106A (en) | Vinylic macromers containing perfluoropolyalkylether and polyalkylether segments, polymers and ophthalmic devices made therefrom | |
MXPA97010041A (en) | Macromonomeros de siloxano polimerizab |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: NOVARTIS AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PHELAN, JOHN CHRISTOPHER;QUINN, MICHAEL HUGH;WALLACH, JOSHUA ANDREW;REEL/FRAME:019166/0776;SIGNING DATES FROM 20070316 TO 20070329 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
FPAY | Fee payment |
Year of fee payment: 12 |
|
AS | Assignment |
Owner name: ALCON INC., SWITZERLAND Free format text: CONFIRMATORY DEED OF ASSIGNMENT EFFECTIVE APRIL 8, 2019;ASSIGNOR:NOVARTIS AG;REEL/FRAME:051454/0788 Effective date: 20191111 |